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A B S T R A C T
Background
Diabetic retinopathy (DR) is a chronic progressive disease of the retinal microvasculature associated with prolonged hyperglycaemia.
Proliferative DR (PDR) is a sight-threatening complication of DR and is characterised by the development of abnormal new vessels in
the retina, optic nerve head or anterior segment of the eye. Argon laser photocoagulation has been the gold standard for the treatment
of PDR for many years, using regimens evaluated by the Early Treatment of Diabetic Retinopathy Study (ETDRS). Over the years,
there have been modifications of the technique and introduction of new laser technologies.
Objectives
To assess the effects of different types of laser, other than argon laser, and different laser protocols, other than those established by the
ETDRS, for the treatment of PDR. We compared different wavelengths; power and pulse duration; pattern, number and location of
burns versus standard argon laser undertaken as specified by the ETDRS.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials
Register) (2017, Issue 5); Ovid MEDLINE; Ovid Embase; LILACS; the ISRCTN registry; ClinicalTrials.gov and the ICTRP. The date
of the search was 8 June 2017.
Selection criteria
We included randomised controlled trials (RCTs) of pan-retinal photocoagulation (PRP) using standard argon laser for treatment of
PDR compared with any other laser modality. We excluded studies of lasers that are not in common use, such as the xenon arc, ruby
or Krypton laser.
Data collection and analysis
We followed Cochrane guidelines and graded the certainty of evidence using the GRADE approach.
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Main results
We identified 11 studies from Europe (6), the USA (2), the Middle East (1) and Asia (2). Five studies compared different types of laser
to argon: Nd:YAG (2 studies) or diode (3 studies). Other studies compared modifications to the standard argon laser PRP technique.
The studies were poorly reported and we judged all to be at high risk of bias in at least one domain. The sample size varied from 20 to
270 eyes but the majority included 50 participants or fewer.
Nd:YAG versus argon laser (2 studies): very low-certainty evidence on vision loss, vision gain, progression and regression of PDR, pain
during laser treatment and adverse effects.
Diode versus argon laser (3 studies): very-low certainty evidence on vision loss, vision gain, progression and regression of PDR and
adverse effects; moderate-certainty evidence that diode laser was more painful (risk ratio (RR) troublesome pain during laser treatment
(RR 3.12, 95% CI 2.16 to 4.51; eyes = 202; studies = 3; I2 = 0%).
0.5 second versus 0.1 second exposure (1 study): low-certainty evidence of lower chance of vision loss with 0.5 second compared with
0.1 second exposure but estimates were imprecise and compatible with no difference or an increased chance of vision loss (RR 0.42,
95% CI 0.08 to 2.04, 44 eyes, 1 RCT); low-certainty evidence that people treated with 0.5 second exposure were more likely to gain
vision (RR 2.22, 95% CI 0.68 to 7.28, 44 eyes, 1 RCT) but again the estimates were imprecise . People given 0.5 second exposure were
more likely to have regression of PDR compared with 0.1 second laser PRP again with imprecise estimate (RR 1.17, 95% CI 0.92 to
1.48, 32 eyes, 1 RCT). There was very low-certainty evidence on progression of PDR and adverse effects.
’Light intensity’ PRP versus classic PRP (1 study): vision loss or gain was not reported but the mean difference in logMAR acuity at 1
year was −0.09 logMAR (95% CI −0.22 to 0.04, 65 eyes, 1 RCT); and low-certainty evidence that fewer patients had pain during
light PRP compared with classic PRP with an imprecise estimate compatible with increased or decreased pain (RR 0.23, 95% CI 0.03
to 1.93, 65 eyes, 1 RCT).
’Mild scatter’ (laser pattern limited to 400 to 600 laser burns in one sitting) PRP versus standard ’full’ scatter PRP (1 study): very low-
certainty evidence on vision and visual field loss. No information on adverse effects.
’Central’ (a more central PRP in addition to mid-peripheral PRP) versus ’peripheral’ standard PRP (1 study): low-certainty evidence
that people treated with central PRP were more likely to lose 15 or more letters of BCVA compared with peripheral laser PRP (RR
3.00, 95% CI 0.67 to 13.46, 50 eyes, 1 RCT); and less likely to gain 15 or more letters (RR 0.25, 95% CI 0.03 to 2.08) with imprecise
estimates compatible with increased or decreased risk.
’Centre sparing’ PRP (argon laser distribution limited to 3 disc diameters from the upper temporal and lower margin of the fovea)
versus standard ’full scatter’ PRP (1 study): low-certainty evidence that people treated with ’centre sparing’ PRP were less likely to lose
15 or more ETDRS letters of BCVA compared with ’full scatter’ PRP (RR 0.67, 95% CI 0.30 to 1.50, 53 eyes). Low-certainty evidence
of similar risk of regression of PDR between groups (RR 0.96, 95% CI 0.73 to 1.27, 53 eyes). Adverse events were not reported.
’Extended targeted’ PRP (to include the equator and any capillary non-perfusion areas between the vascular arcades) versus standard
PRP (1 study): low-certainty evidence that people in the extended group had similar or slightly reduced chance of loss of 15 or more
letters of BCVA compared with the standard PRP group (RR 0.94, 95% CI 0.70 to 1.28, 270 eyes). Low-certainty evidence that people
in the extended group had a similar or slightly increased chance of regression of PDR compared with the standard PRP group (RR
1.11, 95% CI 0.95 to 1.31, 270 eyes). Very low-certainty information on adverse effects.
Authors’ conclusions
Modern laser techniques and modalities have been developed to treat PDR. However there is limited evidence available with respect to
the efficacy and safety of alternative laser systems or strategies compared with the standard argon laser as described in ETDRS
P L A I N L A N G U A G E S U M M A R Y
Do newer laser treatments work better than standard laser treatments for proliferative diabetic retinopathy?
What was the aim of this review?
The aim of this Cochrane Review was to find out if new ways of doing laser treatment for proliferative diabetic retinopathy (explained
under ’What was studied in the review?’ below) work better than standard treatment. Cochrane researchers collected and analysed all
relevant studies to answer this question and found 10 studies.
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Key messages
There is limited evidence on the benefits and harms of different laser systems or strategies compared with the standard treatment.
What was studied in the review?
People with diabetes can have problems in the back of their eyes that may affect their sight. One of these problems is the growth of
harmful new blood vessels in the retina (the layer that covers the back of the eye that allows people to see); this is called proliferative
diabetic retinopathy, referred to as ‘PDR’. Sight loss can occur as a result of PDR. Argon laser has been used to treat PDR for many
years. New types of laser and new ways of doing laser treatment have been developed to treat PDR. The aim of this review was to assess
the evidence for the benefits and harms of these new treatments.
What are the main results of the review?
The Cochrane researchers found 11 relevant studies. Four studies were done in Italy, two studies were done in the US, one in South
Korea, one in Iran, one in Slovenia, one in Greece and one in India. All the people included in these studies had PDR due to type 1 or
type 2 diabetes. Most of these studies were small and provide limited evidence on which to base treatment decisions.
How up to date is this review?
Cochrane researchers searched for studies that had been published up to 8 June 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Nd:YAG laser compared to argon-green laser for proliferative diabetic retinopathy
Patient or population: people with prolif erat ive diabet ic ret inopathy
Setting: eye hospital
Intervention: Nd:YAG laser
Comparison: argon-green laser
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with argon-green
laser
Risk with Nd:YAG laser
BCVA: loss of 15 or
more ETDRS letters
follow-up: 1 year
Study populat ion RR 0.80
(0.30 to 2.13)
20
(1 RCT)
⊕©©©
VERY LOW 123
500 per 1000 400 per 1000
(150 to 1000)
BCVA: gain of 15 or
more ETDRS letters
Study populat ion RR 0.33 (0.02 to 7.32) 20
(1 RCT)
⊕©©©
VERY LOW 123
100 per 1000 33 per 1000
(2 to 732)
Progression of PDR
follow-up: 1 year
Study populat ion RR 1.00
(0.07 to 14.95)
42
(1 RCT)
⊕©©©
VERY LOW 124
48 per 1000 48 per 1000
(3 to 712)
Regression of PDR
follow-up: 1 year
Study populat ion RR 1.00
(0.87 to 1.14)
42
(1 RCT)
⊕©©©
VERY LOW 125
952 per 1000 952 per 1000
(829 to 1000)
Pain during laser treat-
ment
Study populat ion RR 1.00
(0.36 to 2.76)
62
(2 RCTs)
⊕©©©
VERY LOW 16
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190 per 1000 190 per 1000
(69 to 524)
Vision-related QoL - not
reported
- - - - -
Adverse events Vitreous haemorrhage, 13% of argon group, RR 1.22 (0.38 to 3.94)
; choroidal detachment, 19% of argon group, RR 0.23 (0.04 to 1.27);
neurotrophic keratopathy, 10% of argon group, RR 1.29 (0.35 to 4.75)
62 (2 RCT) ⊕©©©
VERY LOW 127
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High-certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate-certainty: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low-certainty: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low-certainty: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded for risk of bias (−1): high risk of performance and detect ion bias.
2 Downgraded for imprecision (−1): small study, wide conf idence intervals
3Downgraded for indirectness (−1): outcome was loss 2 or more lines of Snellen at 6 months
4 Downgraded for indirectness (−1): outcome was not clearly def ined - ‘‘PDR worsened’’ - and was reported at 29 months
5 Downgraded for indirectness (−1): outcome was not clearly def ined - ‘‘PDR improved’’ - and was reported at 29 months
6 Downgraded for imprecision (−2): small study, few events
7 Downgraded for inconsistency (−1): there was some inconsistency between studies
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B A C K G R O U N D
Description of the condition
Diabetic retinopathy (DR) is a chronic, progressive, potentially
sight-threatening disease of the retinal microvasculature associated
with prolonged hyperglycaemia. As the leading cause of blindness
among working-aged adults around the world, DR is a major pub-
lic health problem (Klein 2007). Its incidence is rising dramati-
cally along with the incidence of type 2 diabetes, driven by greater
longevity combined with sedentary lifestyles and increasing levels
of obesity (Geiss 2011). Globally, there are approximately 93 mil-
lion people with DR, including 17 million with proliferative DR,
21 million with diabetic macular oedema (DMO), and 28 million
with vision-threatening diabetic retinopathy (VTDR) (Yau 2012).
A pooled analysis from diabetic population-based studies around
the world found overall prevalence rates of 34.6% for any DR,
6.96% for PDR, 6.81% for DMO and 10.2% for VTDR. All DR
prevalence endpoints increased with diabetes duration, haemoglo-
bin A(1c), and blood pressure levels and were higher in people
with type 1 compared with type 2 diabetes (Yau 2012).
These data highlight the substantial worldwide public health bur-
den of DR and the importance of tackling modifiable risk factors
to reduce its occurrence. TheDiabetesControl andComplications
Trial (DCCT) showed that intensive glycaemic control was effec-
tive in delaying the onset, as well as slowing the progression, of DR
in patients with type 1 diabetes (DCCT Research Group 1993).
The UK Prospective Diabetes Study (UKPDS) showed the risk of
complications in type 2diabeticswas independently and additively
correlated with hyperglycaemia and hypertension, with risk reduc-
tions of 21% per 1% decrease in HbA1c and 11% per 10 mmHg
decrease in systolic blood pressure (Stratton 2006; UKPDSGroup
1998). There are various classifications of DR, but all recognise
the two basic mechanisms leading to loss of vision: retinopathy
(risk of developing new vessels); and maculopathy (risk of damage
to the central fovea). The differences between classifications relate
mainly to levels of retinopathy and to terminology used. Severity
is ranked into a stepwise scale from no retinopathy through var-
ious stages of non-proliferative or pre-proliferative disease to ad-
vanced proliferative disease (ETDRS Research Group 1991). This
review is concerned with Vision Threatening Diabetic Retinopa-
thy (VTDR) related to the development of PDR.
PDR is characterised by the development of new vessels and can
be further defined by their location and severity. With regards to
location, there may be: new vessels on the disc or within 1 disc
diameter (DD) of the margin of the disc (NVD); elsewhere in
the retina (NVE); on the iris (NVI); or anterior chamber angle
(NVA). Classification of PDR severity includes: early PDR (NVD
< 1/4DD, NVEwithout haemorrhage); PDR with high risk char-
acteristics such as NVD equal to or greater than 1/4 DD, any
NVD- or NVE-associated vitreous haemorrhage; florid (aggres-
sive presentation) PDR; and gliotic (with the development of fi-
brotic tissue) PDR. ’Involutionary’ PDR refers to new vessels that
have regressed, usually in response to treatment but (rarely) spon-
taneously.
Description of the intervention
Laser photocoagulation reduces the oxygen demand of the outer
layers of the retina and helps divert adequate oxygen and nutrients
to the retina, favourably altering the haemodynamics (Stefánsson
2001). Laser photocoagulation appears also to act by reducing
the expression of vasoactive factors such as vascular endothelial
growth factor (VEGF) and protein kinase C (PKC) in the retina
(Ghosh 2005). Indeed, different landmark studies have supported
the efficacy of laser PRP in preventing vision loss. The Diabetic
Retinopathy Study (DRS) demonstrated that laser photocoagula-
tion of the retina reduced severe visual loss (defined as visual acu-
ity of 5/200 or less on two consecutive visits at least four months
apart) (DRS Research Group 1978); and the Early Treatment Di-
abetic Retinopathy Study (ETDRS) addressed the question of the
appropriate time for performing laser photocoagulation, showing
that PRP was beneficial only in cases where proliferative changes
were present and specifically when high-risk characteristics PDR
were present (ETDRS Research Group 1985). It also showed that
focal or grid photocoagulation was beneficial in reducing visual
loss due to macular oedema (ETDRS Research Group 1985). As
PRP may be associated with morbidity, the risk benefit ratio of
PRP in people at higher risk would favour the performance of
PRP. The visual loss due to PRP is much less debilitating at this
stage compared with the high risk of severe vision loss in the near
future if the retinopathy were to remain untreated (Feman 2004).
The ETDRS also showed that focal or grid photocoagulation was
beneficial in reducing the risk of visual loss due toDMO (ETDRS
Research Group 1985).
How the intervention might work
It is believed that in the majority of cases, PDR represents an
angiogenic response of the retina to extensive capillary closure.
New vessels grow at the interface of perfused and non-perfused
retina. Peripheral retinal ischaemia, in the absence of surrogate
markers or capillary drop-out (blot haemorrhage, venous beading,
intraretinal microvascular anomalies), may not always be readily
discernible clinically, and hence fluorescein angiography - espe-
cially wide field fluorescein angiography - is especially useful in
detecting ischaemic changes.
The aim of laser PRP treatment is to destroy the areas where
there is capillary non-perfusion and retinal ischaemia as it is in
these ischaemic areas where VEGF, a permeability and angiogenic
factor, is produced. Lasers act by inducing thermal damage after
absorption of energy by tissue pigments. If there is an inadequate
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response after a standard PRP is undertaken and full regression
of new vessels is not achieved, clinicians often supplement the
treatment by undertaking further laser in untreated areas.
Following the guidelines published by the DRS and ETDRS, ar-
gon laser photocoagulation has been the gold standard for the
treatment of PDR. Level 1 evidence from the DRS recommended
multisession scatter PRP laser (800 to 1600 spots in one or two
sittings, and follow-up treatment applied as needed at 4-month
intervals) extending to or beyond the vortex vein ampullae (mid-
peripheral retina) (DRS Research Group 1981). Practitioners still
widely follow this guideline as a frame of reference. In general,
ophthalmologists administer laser covering 360° of the midpe-
ripheral retina, with adequate spacing between laser burns (~ 1
burn apart) to avoid compromising peripheral vision. In clinical
practice, the power of the laser selected is set for each individual
patient to achieve an adequate burn in the retina and is depen-
dent on variables such as media clarity, fundus pigmentation, and
method of delivery. Avoiding very intense white spots is advised
to reduce possible complications such as haemorrhage and breaks
through Bruch’s membrane which could lead to choroidal neovas-
cularisation.
It has been suggested also that laser strategies other than single
pulse argon laser peripheral PRP used by the ETDRS may help
reduce ocular side effects, such as laser burn scarring and visual
field loss (Muqit 2010). The newer ’yellow’ wavelength lasers have
the highest combined absorption in the melanin-oxyhaemoglobin
layers of the RPE/choriocapillaris complex and are thought to in-
duce less scatter with increased efficiency compared to green laser
photocoagulators (Castillejos-Rios 1992). Diode laser may pro-
duce energy in the 532 nm (green) band, the 577 nm (yellow)
band, or in the invisible infrared band (810 nm). These laser treat-
ment strategies can target threshold level, or subthreshold level
depending on the power used. MicroPulse mode is available for
the 810 nm infrared band wavelength.
Laser PRP can be delivered as a single spot but now multispot
laser delivery systems allow a reduced pulse duration compared
with conventional argon laser (100 ms to 200 ms) with the aim of
a quicker and less painful experience. Additionally, the procedure
can be semiautomated by delivering multiple laser burns to the
retina with a single depression of the foot pedal.
Why it is important to do this review
Current guidelines for the management of PDR recommend that
an ophthalmologist promptly perform PRP until regression of
neovascularisation is achieved (Ghanchi 2013). However, most
of the evidence relies on the previously described landmark tri-
als, which used older lasers from the 1980s. It does not provide
enough evidence to recommend newer laser protocols which may
be equally effective but safer and less uncomfortable for patients.
Thus a high-quality review, comparing the standard ETDRS laser
treatment for PDR with alternative laser strategies and including
modern lasers, was necessary. This systematic review was designed
to examine efficacy and safety of alternative types of laser in peo-
ple with PDR when compared with standard argon laser. It as-
sessed the evidence base for alternative laser treatment strategies
such as ischaemia-targeted laser to the peripheral retina as seen
on fluorescein angiography compared with standard argon laser.
This review followed on from the preliminary work carried out
by Evans 2014 in a recent Cochrane Review assessing the effects
of laser photocoagulation for DR compared to no treatment or
deferred treatment. PRP has been the mainstay of treatment of
PDR for many years, but reviews on variations in the laser treat-
ment protocol were recommended. A NIHR-HTA project (12/
71/01) addressed a similar question but in different populations,
with earlier disease than in our review (Royle 2015).
O B J E C T I V E S
To assess the effects of different types of laser, other than argon
laser, and different laser protocols, other than those established by
the ETDRS, for the treatment of PDR. We compared different
wavelengths; power and pulse duration; pattern, number and lo-
cation of burns versus standard argon laser undertaken as specified
by the ETDRS.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised controlled trials (RCTs) in this re-
view.
Types of participants
We included people with type 1 or 2 diabetes mellitus of all ages
and both sexes with PDR as defined in the included studies. We
included a subgroup of trials where participants have received pre-
vious pharmacological treatments for diabetic eye disease. We did
not exclude studies that enrolled participants with other associated
retinal diseases such as retinal vein occlusion as long as the diabetic
subgroup with PDR is clearly identified and the reason for laser is
PDR.
Types of interventions
We included RCTs that consider laser pan-retinal photocoagula-
tion (PRP) for PDR but only those with a comparator group of
standard argon laser PRP.
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Interventions
We compared variations of the following parameters to the stan-
dard argon laser single spot treatment (comparator). We excluded
studies that considered lasers that are not in common use, such as
the xenon arc photocoagulation, ruby or Krypton laser.
Wavelength
Any ophthalmic laser type (wavelength) including but not limited
to:
• 810 nm
• 577 nm
• 532 nm
Laser burn application
Any laser burn application method including but not limited to:
• variations in total number of burns required to induce
regression of neovascularisation, including number of laser
sessions required;
• use of multispot pattern laser delivery;
• use of conventional slit lamp or the fundus camera-
navigated laser system.
Location of laser burns
Any laser burn target location including but not limited to is-
chaemia-targeted retinal location.
Laser combined with other treatments
We included studies in which participants may have also received
non-laser based therapies for other indications such as diabetic
macular oedema (DMO), for example anti-VEGF, intraocular
steroid implants or traditional Chinese medicine; however, we
considered these as a separate subset.
We excluded studies that compare laser versus laser plus another
non-laser intervention for PDR, as this is covered in another
Cochrane Review (Martinez-Zapata 2014)
Comparator
The comparator was standard argon laser single spot treatment ac-
cording to ETDRS guidelines. Specifically, the recommendations
in the ETDRS are an initial treatment of midperipheral scatter
laser consisting of 1200 to 1600 burns of moderate intensity, 200
µm to 500 µm spot size, with one-half spot to one-spot diameter
spacing. Argon pulse duration is 100 ms to 200 ms with power
titrated to produce moderate-intensity burns but with full treat-
ment divided over at least two sessions according to different clin-
ical scenarios (ETDRS Research Group 1987).
Types of outcome measures
Primary outcomes
The primary outcome was best-corrected visual acuity (BCVA).
Specifically we used the proportion of people who lost or gained at
least 15 ETDRS letters (equivalent to 3 ETDRS lines) asmeasured
on a LogMAR chart at the one- and five-year time point.
Secondary outcomes
We considered the following secondary outcomes.
1. Change in mean BCVA (LogMAR) from baseline to 12
months and five years.
2. Change in mean best-corrected near visual acuity (NVA)
from baseline to 12 months and five years.
3. Progression of diabetic retinopathy and/or maculopathy
from baseline to 12 months and five years as defined by trial
investigators, including optical coherence tomography (OCT)
mean central subfield thickness (CMT) where measured.
4. Visual field (VF) loss from baseline to 12 months and five
years compared to baseline including mean deviation (MD).
5. Patient-reported outcome measure (PROM) for pain
associated with the treatment, vision-related quality of life (QoL)
measured using any validated questionnaire, or loss of driving
licence at 12 months and five years.
6. Resource use and costs.
We recorded two additional outcomes (not planned at the protocol
stage).
1. Regression of diabetic retinopathy.
2. Need for further laser treatment after 3 months.
The reason we recorded these additional two outcomes is because
progression and regression of diabetic retinopathy, and also need
for further laser PRP treatment, all represent the same domain,
i.e. disease control. This is an important clinical outcome so we
wanted to capture all possible data, and several trials do not report
progression but report regression or need for further treatment.
Adverse events
Adverse events reported in the studies at any time includingbut not
limited to: macular oedema, retinal detachment, vitreous haem-
orrhage, need for vitrectomy surgery, severe visual loss (BCVA <
6/60).
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist conducted
systematic searches in the following databases for randomised con-
trolled trials and controlled clinical trials. There were no language
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or publication year restrictions. The date of the search was 8 June
2017.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 5) (which contains the Cochrane Eyes
and Vision Trials Register) in the Cochrane Library (searched 8
June 2017) (Appendix 1);
• MEDLINE Ovid (1946 to 8 June 2017) (Appendix 2);
• Embase Ovid (1980 to 8 June 2017) (Appendix 3);
• ISRCTN registry (www.isrctn.com/editAdvancedSearch;
searched 8 June 2017) (Appendix 4);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov; searched 8 June 2017)
(Appendix 5);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (www.who.int/ictrp; searched
8 June 2017) (Appendix 6).
Searching other resources
We searched the reference lists of potentially includable studies to
identify any additional trials. We did not handsearch conference
proceedings for this review.
Data collection and analysis
Selection of studies
Two authors independently reviewed the titles and abstracts iden-
tified from the electronic andmanual searches against the inclusion
criteria using web-based review management software (Covidence
2015). We obtained full-text copies of all potentially or definitely
relevant articles. We contacted trial investigators for further infor-
mation if required. We resolved discrepancies between authors as
to whether or not studies met inclusion criteria by discussion. We
documented the excluded studies and the reasons for exclusion.
Data extraction and management
We extracted the following participant and trial characteristics and
report them in a table format (Appendix 7).
• Participant characteristics (age, sex, glycated haemoglobin
(HbA1c), cholesterol, blood pressure, diagnostic criteria used for
PDR, baseline visual acuity, OCT-determined CMT, and areas
of ischaemic retinal tissue according to fluorescein angiography).
• Intervention (laser agent, laser settings, number of spots
delivered, treatment interval and number, retinal target location).
• Methodology (group size, randomisation, masking
(blinding)).
• Outcomes data as specified above.
We contacted trial investigators for key unpublished information
that is missing from reports of included studies. Two review au-
thors independently extracted the data, entering data into web-
based review management software (Covidence 2015), and us-
ing pre-piloted data extraction templates. Covidence enabled us
to compare discrepancies, which we resolved by discussion. We
directly imported data from Covidence into Review Manager 5
(RevMan 5) (Review Manager 2014).
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias of the
included trials according to Chapter 8 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). We consid-
ered the following main criteria.
• Selection bias: random sequence generation, allocation
concealment.
• Performance bias: masking of participants, researchers and
outcome assessors.
• Attrition bias: loss to follow-up, rates of adherence.
• Reporting bias: selective outcome reporting. We reported
each parameter as being at high, low, or unclear risk of bias,
resolving any discrepancies between the authors by discussion.
We contacted study authors to clarify study details relating to
any unclear risk of bias. When there was no response from the
authors, we classified the trial based on available information.
See Table 1 for additional information on assessment of risk of
bias.
Measures of treatment effect
Wemeasured treatment effect according to the data types described
in Chapter 9 of the Cochrane Handbook for Systematic Reviews of
Interventions (Deeks 2011). These include the following.
Dichotomous data
Variables in this group included the primary outcome and the
proportion of participants experiencing an adverse event during
follow-up. We reported dichotomous variables as risk ratios (RRs)
with 95% confidence intervals (CIs).
Continuous data
We reported continuous variables including mean change in visual
acuity as mean difference with 95% CIs (if normally distributed)
or median and interquartile range (if not normally distributed).
Qualitative data
We reported the types of adverse event, resource use and quality of
life data qualitatively as a narrative description of qualitative data.
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Unit of analysis issues
Nine of the 10 studies includedmore than one eye per person.Han
1995 was the only study to include only one eye per person. None
of the studies that included one or both eyes adjusted data analysis
for within-person correlation. We used the data as reported by the
studies.
Dealing with missing data
We sought key unpublished information that was missing from
reports of included studies by contacting study authors but this
information was not usually available. We documented when loss
to follow-up was high (over 20%) or imbalanced between treat-
ment groups as potential attrition bias.
Assessment of heterogeneity
We assessed heterogeneity by inspection of the forest plots and by
calculating the I² value to assess the proportion of the variance that
reflects variation in true effects (Higgins 2003). We considered I²
values of greater than 50% to represent substantial inconsistency
but also considered the Chi² P value. As this may have low power
when there are few studies, we considered P values less than 0.1
to indicate statistical significance of the Chi² test.
Assessment of reporting biases
Wewere unable to look at reporting biases because there were only
10 studies found and not more than two studies available for each
comparison. We considered selective outcome reporting bias as
part of the assessment of risk of bias in the individual studies (see
Assessment of risk of bias in included studies section).
Data synthesis
Where appropriate, we pooled data using a fixed-effect model.
None of the comparisons and outcomes had more than two trials
contributing data.
Subgroup and sensitivity analyses
Wewere unable to performplanned subgroup and sensitivity anal-
ysis as there was not enough information available. See Differences
between protocol and review section for details of planned analy-
ses.
’Summary of findings’ table
We reported absolute risks and measures of effect in a ’Summary
of findings’ (SOF) table providing key information concerning
the certainty of the evidence, the magnitude of effect of the inter-
ventions examined, and the sum of available data on all specified
review primary and secondary outcomes for a given comparison.
Data was not available in suitable format for adverse events, so we
provided a narrative summary within the SOF table.
The ’Summary of findings’ table included the following key out-
comes.
1. Proportion of people who lose 15 or more ETDRS letters
(equivalent to 3 ETDRS lines) as measured on a LogMAR chart
from baseline at one and five years.
2. Proportion of people who gain 15 or more ETDRS letters
(equivalent to 3 ETDRS lines) as measured on a LogMAR chart
from baseline at one and five years.
3. Progression of PDR from baseline at one and five years as
defined by trial investigators, including OCT mean central
subfield thickness (CMT) where measured.
4. Regression of PDR from baseline at one and five years as
defined by trial investigators (new outcome).
5. Adverse events at any time such as: macular oedema, retinal
detachment, vitreous haemorrhage, need for vitrectomy surgery,
severe visual loss (BCVA < 6/60).
6. PROM: significant pain during the laser procedure.
7. Vision-related quality of life (QoL) measure using any
validated questionnaire at one and five years compared to
baseline.
Two review authors independently used the GRADE approach to
assess the certainty of the evidence in the included studies using
GRADEpro GDT software (GRADEpro 2014). We resolved dis-
crepancies by discussion.
We planned to calculate the assumed risk from the median risk
in the comparator group of the included studies, but in the event
there were not more than two or three studies per comparison so
we used the pooled event risk in the comparator group.
R E S U L T S
Description of studies
Results of the search
The electronic searches yielded a total of 4940 records (Figure 1).
The Cochrane Information Specialist scanned the search results,
removed 1472 duplicates and then removed 2977 references which
were irrelevant to the scope of the review. We screened the remain-
ing 491 reports and obtained 88 full-text reports for further assess-
ment. We included 13 reports of 11 studies (see Characteristics
of included studies), and excluded 69 reports of 52 studies (see
Characteristics of excluded studies).We did not identify any ongo-
ing studies fromour searches of the clinical trials registries.Wehave
6 studies awaiting classification for which we were unable to iden-
tify a full text report (Chaine 1986, Kianersi 2016; Wroblewski
1991) or were unable to obtain a translation (Uehara 1993, Yang
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2010) or for which the full text did not provide enough informa-
tion to judge inclusion (Salman 2011).
Figure 1. Study flow diagram.
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Included studies
Types of study
We included a total of 11 studies in the review, all of which were
randomised controlled trials. These studies were conducted in the
US (2), Italy (4), South Korea (1), India (1), Iran (1), Slovenia (1),
andGreece (1). There was generally poor recording of the sponsor-
ship source, but two studies declared public funding (Blankenship
1988; Wade 1990.)
Participants
All studies in the review included both male and female adult
participants with a clinical diagnosis of type 1 or type 2 diabetes
mellitus, between the ages of 18 to 79 years, although age range
of participants was not always reported. One or both eyes of each
participant were required to have high risk proliferative diabetic
retinopathy based on the ETDRS definition, Han 1995 being the
only study to include only one eye per person. None of the studies
that included one or both eyes adjusted the data analysis forwithin-
person correlation. There was one within-person study (Tewari
2000), again with no appropriate, matched, analysis. Across all
included studies the baseline mean age ranged from 40 to 58 years,
andbaselinemean visual acuity ranged from0.12 to0.89LogMAR
acuity. The size of studies varied from 20 to 270 eyes.
Interventions
All participants included in the review were treated with an al-
ternative laser PRP strategy compared with standard argon laser
PRP (defined as midperipheral scatter, panretinal photocoagula-
tion with 0.1 second pulse duration of moderate laser intensity).
We included a variety of alternative laser PRP interventions which
included: double-frequency Nd:YAG laser (532 nm) (Bandello
1996)(Brancato 1991); diode laser (810 nm) (Bandello 1993;Han
1995; Tewari 2000); longer exposure time of 0.5 second argon
laser burn (Wade 1990); ’light intensity’ lower energy treatment
with standard argon laser pulse (Bandello 2001); ’mild scatter’ ar-
gon laser pattern limited to only 400 to 600 laser burns in one sit-
ting (Pahor 1998); ’central PRP’ which compared a more central
(mean number of 437 laser burns placed more posteriorly with
sparing of a 2 DD area centred on the fovea and papillomacular
bundle) versus a more standard ’peripheral’ PRP (mean number of
441 laser burns placed more peripherally, anterior to the equator
extending to the ora serrata when possible) treatment in addition
to mid-peripheral PRP (Blankenship 1988); ’central sparing’ ar-
gon laser PRP distribution which stopped 3 DD from the upper
temporal and lower margin of the fovea (Theodossiadis 1990);
and an ’extended targeted’ argon laser PRP to include the entire
retina anterior to the equator and any capillary non-perfusion ar-
eas between the vascular arcades and equator, including 1 DD be-
yond the ischaemic areas (Nikkhah 2017). See more details in the
Characteristics of included studies table.
Outcomes
All studies except two studies (Bandello 1993; Tewari 2000) mea-
sured and reported our primary outcome of loss or gain of at least
15 ETDRS letters (equivalent to 3 ETDRS lines) as measured on
a LogMAR chart. If the follow-up was not recorded at the one-
and five-year time point we used the final time point provided.
Approximately half of the studies provided some measure of re-
gression or progression of PDR. Visual field loss was only reported
in one study and pain during laser treatment was reported in five
studies.
No study recorded near visual acuity, or patient-relevant outcomes
such as loss of driving licence or vision-related quality of life. No
study discussed resource use and costs. Follow-up time ranged
from one month to two years.
Excluded studies
Fifty-two studies were excluded after full text screening. Reasons
for exclusion were as follows: intervention, i.e. evaluating a laser
that is not currently available (n = 16); comparator, i.e. not com-
pared with standard argon laser PRP (n = 15); study design, i.e.
not randomised controlled trial (n = 12); outcome, i.e. study did
not measure relevant outcomes (n =3); patient population, i.e. pa-
tients did not have PDR (n = 3), comparisons not pre-specified by
this review (n = 3). See Characteristics of excluded studies table
for the list of exclusions with reasons.
Risk of bias in included studies
See Figure 2; Figure 3
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Five studies reported an adequate method of random sequence
generation: Bandello 2001 and Nikkhah 2017 used computer-
generated random numbers; Blankenship 1988, Tewari 2000 and
Wade 1990 flipped a coin. In the remaining studies it was not
possible to judge whether random sequence generation had been
done properly. Bandello 1993 may have used alternate allocation.
Two studies reported allocation concealment. In Blankenship
1988 allocation was done after the participants were recruited.
Nikkhah 2017 reported that the allocation sequence was kept con-
cealed from the investigators.
Blinding
None of the studies masked participants, personnel or outcomes
assessors so they were judged at high risk of bias for these domains.
Incomplete outcome data
Most studies (n = 7) had low risk of attrition bias.
In Han 1995 the number of participants randomised matched the
number of participants analysed but the loss to follow-up was not
clearly reported. In Han’s exclusion criteria there was indication
that people with adverse events were excluded after treatment but
it was not reported how many people were excluded in this way.
In Pahor 1998 attrition was high (38%) after a follow-up of one
month after treatment, and it was not reported to which groups
the loss to follow-up occurred.
In a further two studies, not enough information was given to
judge this (Bandello 2001; Theodossiadis 1990).
Selective reporting
We did not have access to trial protocols as the studies were con-
ducted so long ago (Nikkhah 2017 was the only study on a clinical
trial registry) so we were unable to judge whether or not selective
reporting was likely to be a problem.
Effects of interventions
See: Summary of findings for the main comparison Nd:YAG
laser compared to argon-green laser for proliferative diabetic
retinopathy; Summary of findings 2 Diode laser compared to
argon laser for proliferative diabetic retinopathy; Summary of
findings 3 0.5 compared to 0.1 second exposure for proliferative
diabetic retinopathy; Summary of findings 4 Light PRP
compared to classic PRP for proliferative diabetic retinopathy;
Summary of findings 5Mild scatter PRP compared to full scatter
PRP for proliferative diabetic retinopathy; Summary of findings
6 Central PRP compared to peripheral PRP for proliferative
diabetic retinopathy; Summary of findings 7Centre sparing PRP
compared to full scatter PRP for proliferative diabetic retinopathy;
Summary of findings 8 Extended targeted PRP compared to
standard PRP
Nd:YAG (532 nm) laser PRP versus argon (514 nm)
laser PRP
Two studies investigated this comparison (Bandello 1996;
Brancato 1991). Bandello 1996 enrolled 42 eyes (33 participants)
with PDR and followed up for 29 months. Brancato 1991 en-
rolled 20 eyes with PDR (16 people with NVD/NVE > 1/2 DA
or associated with haemorrhage) and followed up for 6 months.
There was very low-certainty evidence for all outcomes (Summary
of findings for the main comparison).
• People treated with Nd:YAG laser PRP were less likely to
lose 15 or more letters of BCVA compared with argon laser PRP
(risk ratio (RR) 0.80, 95% confidence interval (CI) 0.30 to 2.13;
participants = 20; studies = 1) (Analysis 1.1).
• People treated with Nd:YAG laser PRP were less likely to
gain 15 or more letters BCVA compared with argon laser (RR
0.33, 95% CI 0.02 to 7.32; participants = 20; studies = 1; I² =
0%) (Analysis 1.2).
• Both studies reported change in BCVA as decimal Snellen
acuity which meant that it was not possible to provide a pooled
analysis. There was little evidence of any important difference
between the two groups (Analysis 1.3).
• There was a similar risk of progression and regression of
PDR in the two groups (RR progression 1.00, 95% CI 0.07 to
14.95 (Analysis 1.4); and RR regression 1.00, 95% CI 0.87 to
1.14 (Analysis 1.5) respectively).
• Similar proportions of people reported pain during laser
treatment (RR 1.00, 95% CI 0.36 to 2.76; participants = 62;
studies = 2) (Analysis 1.6).
Other relevant outcomes such asNVA,VF loss, vision-relatedQoL
measure, details of any resource use and costs and need for further
laser PRP treatment after three months were not reported.
Adverse events are set out in the following table. There were in-
consistent results for vitreous haemorrhage and neurotrophic ker-
atopathy. Choroidal detachment occurred less frequently in the
YAG laser group but the estimates were imprecise and did not
exclude no difference.
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Adverse event Study Nd:YAG
n/N (%)
Argon
n/N (%)
RR (95% CI) Pooled RR (95% CI)
Vitreous
haemorrhage
Bandello 1996 5/21 (24%) 2/21 (10%) 2.50 (0.54, 11.48) 1.22 (0.38 to 3.94) I² = 57%)
Brancato 1991 0/10 (0%) 2/10 (20%) 0.20 (0.01, 3.70)
Choroidal detach-
ment
Bandello 1996 1/21 (5%) 5/21(24%) 0.20 (0.03, 1.57) 0.23 (0.04 to 1.27) I² = 0%)
Brancato 1991 0/10 (0%) 1/10 (10%) 0.33 (0.02, 7.32)
Neurotrophic ker-
atopathy
Bandello 1996 3/21 (14%) 3/21 (14%) 1.00 (0.23, 4.40) 1.29 (0.35 to 4.75) I² = 0%)
Brancato 1991 1/10 (10%) 0/10 (0%) 3.00 (0.14, 65.90)
We graded the evidence for this comparison as very low-certainty
for all outcomes (Summary of findings for the main comparison).
We downgraded 1 level for high risk of performance and detection
bias as the studies were not masked; 1 level for imprecision as the
studies were small and estimates of effect imprecise; and 1 level for
indirectness as the outcomes were not reported at our pre-specified
time points and were not clearly defined.
Diode (810 nm) versus argon (514 nm) laser PRP
Three studies investigated this comparison (Bandello 1993; Han
1995; Tewari 2000). Han 1995 enrolled 108 eyes (108 people)
with PDR and followed up for between 13 to 15months. Bandello
1993 enrolled 34 people (44 eyes) with PDR and followed up for
2 years (on average). Tewari 2000 was a within-person study of 22
people (44 eyes) with follow-up of 6 months.
There was very low-certainty evidence for the following outcomes
(Summary of findings 2).
• People treated with diode laser PRP had similar or slightly
increased risk of “worsened” vision compared with argon green
laser PRP (1.10, 95% CI 0.67 to 1.82; eyes = 108; studies = 1)
(Analysis 2.1).
• People treated with diode laser PRP were less likely to have
“improved” vision compared with argon laser PRP (RR 0.63,
95% CI 0.25 to 1.59; eyes = 108; studies = 1) (Analysis 2.2).
• Mean Snellen acuity was similar in both groups (Analysis
2.3).
• People treated with diode laser PRP had a similar or slightly
lower risk of progression of PDR compared with argon laser PRP
(RR 0.90, 95% CI 0.41 to 2.00) (Analysis 2.4).
• People treated with diode laser PRP were less likely to have
regression of PDR compared with argon laser PRP (RR 0.75,
95% CI 0.35 to 1.60) (Analysis 2.5).
There was moderate-certainty evidence that diode laser was more
painful (RR3.12, 95%CI 2.16 to 4.51; participants = 202; studies
= 3; I2 = 0%) Analysis 2.6.
In the Han 1995 paper only the number of people (%) with “im-
proved”, “unchanged” or “worsened” visual acuity were provided;
but there is no numerical definition for each of these and it was
unclear which charts were used for visual acuity measurement.
Other relevant outcomes such as NVA, VF loss, pain during laser
treatment, vision-related QoL measure, details of any resource use
and costs, and need for further laser PRP treatment after three
months were not reported.
Adverse events are summarised in the following table and Analysis
2.7.
Adverse event Study Diode
n/N (%)
Argon
n/N (%)
RR (95% CI) Pooled RR (95% CI)
Vitreous
haemorrhage
Bandello 1993 7/22 (32%) 4/22 (18%) 1.75 [0.60, 5.14] 1.80 (0.91 to 3.53)
Han 1995 11/50 (22%) 7/58 (12%) 1.82 (0.76, 4.35)
Tewari 2000 NR NR
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(Continued)
Choroidal detach-
ment
Bandello 1993 4/22 (18%) 1/22 (5%) 4.00 [0.48, 33.00] NA
Han 1995 NR NR
Tewari 2000 NR NR
Neurotrophic ker-
atopathy
Bandello 1993 1/22 (5%) 0/22 (0%) 3.00 [0.13, 69.87] NA
Han 1995 NR NR
Tewari 2000 NR NR
Maculopathy Bandello 1993 NR NR NA
Brancato 1990 NR NR
Han 1995 9/50 (18%) 8/58 (14%) 1.30 (0.54, 3.13)
Tewari 2000 NR NR
Cataract Bandello 1993 NR NR NA
Brancato 1990 NR NR
Han 1995 4/50 (8%) 9/58 (16%) 0.52 (0.17, 1.57)
Tewari 2000 NR NR
Pre-retinal
membrane
Bandello 1993 NR NR NA
Brancato 1990 NR NR
Han 1995 3/50 (6%) 3/58 (5%) 1.16 (0.24, 5.49)
Tewari 2000 NR NR
NR = not reported; NA = not applicable.
We graded the evidence for this comparison as very low-certainty
for all outcomes (apart from pain) (Summary of findings 2). We
downgraded all outcomes recorded in the studies by 1 level for
high risk of performance and detection bias as it was unclear if the
studies were masked and no details of randomisation were pro-
vided; and 1 level for imprecision due to wide confidence interval.
The outcomes of BCVA and DR progression/regression were also
downgraded by 1 level for indirectness as the outcomes were not
clearly defined (both studies only stated “worsened” visual acuity,
“worsened” or “improved” neovascularisation).
0.5-second versus 0.1-second duration of exposure of
argon (514 nm) laser PRP
One study investigated this comparison (Wade 1990).Wade 1990
enrolled 50 eyes (41 participants) with high-risk PDR (DRS
Research Group 1978 criteria) and followed up for 6 months.
Low-certainty and very low-certainty evidence was available
(Summary of findings 3).
• Low-certainty evidence that people treated with 0.5-second
laser PRP were less likely to have a loss of 15 or more letters of
BVCA compared with 0.1-second laser PRP. (RR 0.42, 95% CI
0.08 to 2.04) (Analysis 3.1).
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• Low-certainty evidence that people treated with 0.5-second
laser PRP were more likely to have a gain of 15 or more letters of
BVCA compared with 0.1-second laser PRP (RR 2.22, 95% CI
0.68 to 7.28) (Analysis 3.2).
• Very low-certainty evidence of progression of PDR between
the 0.5-second group compared with standard 0.1-second laser
spot duration (RR 0.33, 95% CI 0.02 to 7.14) (Analysis 3.3).
• Low-certainty evidence that people treated with 0.5-second
laser PRP were less likely to have regression of PDR compared
with 0.1-second laser PRP (RR 1.17, 95% CI 0.92 to 1.48)
(Analysis 3.4).
Other relevant outcomes such as NVA, VF loss, pain during laser
treatment, vision-related QoL measure, details of any resource use
and costs were not reported.
Adverse events are summarised in the following table.
Adverse event 0.5 sec
n/N (%)
0.1 sec
n/N (%)
RR (95% CI)
Pre-retinal or vitreous haemor-
rhage
4/24 (17%) 6/20 (30%) 0.56 (0.18 to 1.70)
Macular thickening 0/24 (0%) 2/20 (10%) 0.17 (0.01 to 3.31)
Combined rhegmatous
and traction retinal detachment
requiring pars plana vitrectomy
1/24 (4%) 0/20 (0%) 2.52 (0.11 to 58.67)
We graded the evidence for this comparison as low-certainty for
the outcomes of ’BCVA: loss of 15 or more ETDR letters’ and
’regression of PDR’ Summary of findings 3. We downgraded 1
level for high risk of imprecision due to wide confidence intervals,
and downgraded 1 level for high risk of performance and detection
bias. For the outcome of ’Progression of PDR’ we downgraded an
additional 1 level due to the very wide confidence interval.
’Light laser’ intensity PRP versus ’classic’ argon (514
nm) laser PRP
One study investigated this comparison (Bandello 2001). Bandello
2001 enrolled 65 eyes (50 people) with high-risk PDR (DRS
ResearchGroup 1978 criteria) and followedup for an average of 22
months. Treatment included ’light intensity’ lower energy argon
laser PRP treatment to achieve a very light grey biomicroscopic
effect on the retina versus ’classic’ argon laser PRP to achieve an
opaque, dusky, grey-white, off-white standard burn.
There was no difference in the change in BCVA between the light
laser PRP and the classic laser PRP group (MD −0.09, 95% CI
−0.22 to 0.04) (Analysis 4.1).
There was low-certainty evidence that fewer people had pain dur-
ing laser treatment in the light laser PRP compared with classic
laser PRP group (RR 0.23, 95% CI 0.03 to 1.93) (Analysis 4.2)
(Summary of findings 4).
Other relevant outcomes such as BCVA loss or gain of 15 or more
letters, NVA, VF loss, vision-related QoL measure, details of any
resource use and costs and need for further laser PRP treatment
after 3 months were not reported.
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Adverse event Light
n/N (%)
Classic
n/N (%)
RR (95% CI)
Vitreous haemorrhage 0/34 (0%) 6/31 (19%) 0.07 (0.00 to 1.20)
Choroidal detachment 0/34 (0%) 3/31 (10%) 0.13, (0.01 to 2.43)
Neurotrophic keratopathy 0/34 (0%) 2/31 (6%) 0.18 (0.01 to 3.67)
Clinically significant macular
oedema
1/34 (3%) 7/31 ( 23%) 0.13 (0.02 to 1.00)
We graded the evidence for this comparison as low-certainty for the
outcomes of ’pain during laser treatment’ (Summary of findings
4). We downgraded 1 level for high risk of imprecision due to
wide confidence intervals, and downgraded 1 level for high risk of
performance and detection bias.
’Mild scatter’ versus ’full scatter’ argon (514 nm) laser
PRP
One study investigated this comparison (Pahor 1998). Pahor 1998
enrolled 40 eyes (32 people) with early PDR and followed up
for one month. Treatment included ’mild scatter’ argon laser PRP
with pattern limited to 400 to 600 laser burns (500 µm, 0.1 sec)
over one session versus ’full scatter’ argon laser PRP with 1200 to
1600 laser burns (500 µm, 0.1 sec) over two sessions, two weeks
apart.
Results are as follows.
• There was no difference in the change in BCVA between
the ’full scatter’ PRP compared with the ’mild scatter’ PRP group
(MD 0.04, 95% CI −0.06 to 0.14) (Analysis 5.1).
• Very low-certainty evidence that people treated with ’full
scatter’ PRP were more likely to have visual field loss compared
with the ’mild scatter’ PRP group (MD −2.50, 95% CI −4.22
to −0.78) (Analysis 5.2) (Summary of findings 5).
Other relevant outcomes such as BCVA loss or gain of 15 or more
letters, NVA, progression or regression of DR, pain during laser
treatment, vision-related QoL measure, details of any resource use
and costs and need for further laser PRP treatment after three
months were not reported.
The authors made no comment regarding adverse events in this
study.
We graded the evidence for this comparison as low-certainty for
the outcomes of ’Visual field loss at 1-year follow-up’ Summary
of findings 5. We downgraded 1 level for high risk of imprecision
due to small study size and upper confidence interval close to 0
(null effect); and downgraded 1 level for high risk of performance,
detection and attrition bias.
’Central’ PRP versus ’peripheral’ argon (514 nm)
laser PRP
One study investigated this comparison (Blankenship 1988).
Blankenship 1988 enrolled 50 eyes (40 participants) with high-
risk PDR (DRS Research Group 1978 criteria) and followed up
for 6months. This study comparedmore central PRP (mean num-
ber of 437 laser burns placed more posteriorly with sparing of a 2
DD area centred on the fovea and papillomacular bundle) versus a
more standard ’peripheral’ PRP (mean number of 441 laser burns
placed more peripherally, anterior to the equator extending to the
ora serrata when possible) treatment in addition to mid-peripheral
PRP.
The results were as follows.
• Low-certainty evidence that people treated with central
PRP were more likely to lose 15 or more letters of BCVA
compared with peripheral laser PRP (RR 3.00, 95% CI 0.67 to
13.46) (Analysis 6.1) (Summary of findings 6).
• Low-certainty evidence that people treated with central
PRP were less likely to gain 15 or more letters of BCVA
compared with peripheral laser PRP (RR 0.25, 95% CI 0.03 to
2.08) (Analysis 6.2).
• Very low-certainty evidence of a similar outcome between
people treated with central PRP compared with peripheral laser
PRP with regards needing further laser treatment after the initial
treatment period (i.e. 3 months) (RR 1.00, 95% CI 0.07 to
15.12) (Analysis 6.3).
Other relevant outcomes such as NVA, progression or regression
of DR, VF loss, pain during laser treatment, vision-related QoL
measure, details of any resource use and costs and need for further
laser PRP treatment after three months were not reported.
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Adverse event Central
n/N (%)
Peripheral
n/N (%)
RR (95% CI)
Vitreous haemorrhage (requir-
ing additional PRP)
1/25 (4%) 1/25 (4%) RR 1.00 (0.07 to 15.12)
Macular traction detachment
(requiring pars plana vitrec-
tomy)
3/25 (12%) 1/25 (4%) RR 3.00 (0.33 to 26.92)
Macular thickening (associated
with loss of 2 or more lines of
visual acuity)
2/25 (8%) 2/25 (8%) RR 1.00 (0.15 to 6.55)
We graded the evidence for this comparison as low-certainty for
the outcomes of ’BCVA loss of 15 ormore ETDRS letters at 1 year’
(Summary of findings 6). We downgraded 1 level for high risk of
imprecision due to wide confidence interval; and downgraded 1
level for high risk of performance and detection bias.
’Centre sparing’ versus ’full scatter’ argon (514 nm)
laser PRP
One study investigated this comparison (Theodossiadis 1990).
Theodossiadis 1990 enrolled 53 eyes (42 participants) with high-
risk PDR (DRS Research Group 1978 criteria) and followed up
for 6 months. This study used argon laser PRP burns (1500 to
3000 burns of 200µm to 500µmdiameter). In the centre sparing
group, laser PRP covered the entire retinal periphery and midpe-
riphery beginning 1 disc diameter from the pars plana, but the
posterior pole was spared 2 disc diameter areas centred on the fovea
and including the papillomacular bundle. In the full scatter group,
laser PRP involved the periphery and midperiphery but stopped
1 disc diameter short of the nasal margins of the optic disc and 3
disc diameter away from the upper, lower and temporal margins
of the fovea.
The results were as follows.
• Low-certainty evidence that people treated with centre
sparing PRP were less likely to lose 15 or more ETDRS letters of
BCVA compared with full scatter laser PRP (RR 0.67, 95% CI
0.30 to 1.50) (Analysis 7.1; Summary of findings 7).
• Low-certainty evidence that people treated with centre
sparing PRP had similar regression of PDR compared with full
scatter laser PRP (RR 0.96, 95% CI 0.73 to 1.27) (Analysis 7.2).
This study concluded “no statistically significant difference regard-
ing regression of neovascularisation and visual acuity” between
the two groups. “There was a difference in retinal sensitivity in
favour of group B at 15 and 30 degrees of visual field found”
(Theodossiadis 1990).
Other relevant outcomes such as BCVA gain of 15 or more letters,
NVA, regression of DR, vision-relatedQoLmeasure, details of any
resource use and costs and need for further laser PRP treatment
after three months were not reported.
The authors made no comment regarding adverse events in this
study.
We graded the evidence for this comparison as low-certainty for
the outcomes of ’BCVA loss of 15 or more ETDRS letters at 1
year’ and ’Regression of PDR at 1-year follow-up’ (Summary of
findings 6). We downgraded 1 level for high risk of imprecision
due to wide confidence interval, and downgraded 1 level for high
risk of performance and detection bias.
’Extended targeted’ PRP versus ’standard’ argon (514
nm) laser PRP
One study investigated this comparison (Nikkhah 2017).Nikkhah
2017 enrolled 270 eyes (234 participants) with early or high-risk
PDR (DRS Research Group 1978 criteria) and followed up for
threemonths. Treatment in both arms applied 1200 to 1600 argon
laser burns with spot size of 200µm, duration 200 ms and spacing
of 0.5 burnwidth. In the extended targetedPRP (ETRP) group the
laser was applied to the entire retina anterior to the equator as well
as the capillary non-perfusion areas between the vascular arcade
and the equator. Conventional PRP (CPRP) laser was applied
from the vascular arcade toward the midperiphery.
The results were as follows.
• Low-certainty evidence that people in the extended targeted
PRP had similar or slightly reduced chance of loss of 15 or more
letters of BCVA compared with the standard PRP group (RR
0.94, 95% CI 0.70 to 1.28) (Analysis 8.1) (Summary of findings
8).
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• Low-certainty evidence that people in the extended targeted
PRP had similar or slightly increased chance of regression of
PDR compared with the standard PRP group (RR 1.11, 95% CI
0.95 to 1.31) (Analysis 8.3).
Other relevant outcomes such as BCVA gain of 15 or more letters,
NVA, progression of DR, VF loss, pain during laser treatment,
vision-related QoL measure, details of any resource use and costs
and need for further laser PRP treatment after three months were
not reported.
No adverse events were observed. “None of the eyes developed
tractional retinal detachment during the study. Additionally, no
ocular or non-ocular AEs related to the study intervention were
detected by the investigators or reported by patients” (Nikkhah
2017).
We graded the evidence for this comparison as low-certainty for
the outcomes of ’BCVA loss of 15 or more ETDRS letters at 1
year’ and ’Regression of PDR at 1-year follow-up’ (Summary of
findings 8). We downgraded 1 level for high risk of imprecision
due to wide confidence interval; and downgraded 1 level for high
risk of performance and detection bias.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Diode laser compared to argon laser for proliferative diabetic retinopathy
Patient or population: people with prolif erat ive diabet ic ret inopathy
Setting: eye hospital
Intervention: diode laser
Comparison: argon laser
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with argon Risk with Diode
BCVA: loss of 15 or
more ETDRS letters
follow-up: 1 year
Study populat ion RR 0.95
(0.66 to 1.36)
134
(2 RCTs)
⊕©©©
VERY LOW 123
345 per 1000 379 per 1000
(231 to 628)
BCVA: gain of 15 or
more ETDRS letters
follow-up: 1 year
Study populat ion RR 0.60
(0.25 to 1.45)
134
(2 RCTs)
⊕©©©
VERY LOW 123
190 per 1000 119 per 1000
(47 to 302)
Progression of PDR fol-
low-up: 1 year
Study populat ion RR 0.90
(0.41 to 2.00)
66 (1 RCT) ⊕©©©
VERY LOW 134
286 per 1000 257 per 1000
(117 to 571)
Regression of PDR
follow-up: 1 year
Study populat ion RR 0.75
(0.35 to 1.60)
66
(1 RCT)
⊕©©©
VERY LOW 134
343 per 1000 257 per 1000
(120 to 549)
Pain during laser treat-
ment
211 per 1000 688 per 1000
(428 to 1000)
RR 3.07 (2.15 to 4.39) 228 (4 RCTs) ⊕⊕⊕©
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Vision-related QoL - not
reported
- - - - -
Adverse events Vitreous haemorrhage, 15% of argon group. inconsistent results between
two studies, RR 0.50 (0.05, 4.86) and RR 1.82 (0.76, 4.35); choroidal
detachment, 8% of argon group RR 4.00 (0.51, 31.13; neurotrophic ker-
atopathy, 0% of argon group, RR 3.00 (0.13, 67.51), maculopathy, 14% of
argon group, RR 1.30 (0.54, 3.13), cataract, 16% of argon group, RR 0.52
(0.17, 1.57), pre-ret inal membrane, 5% of argon group, RR 1.16 (0.24, 5.
49)
134 (2 studies) ⊕©©©
VERY LOW 15
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High-certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate-certainty: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low-certainty: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low-certainty: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded for risk of bias (−1): high risk of performance, detect ion and attrit ion bias
2 Downgraded for indirectness (−1): outcome was not clearly def ined - ‘‘worsened’’ visual acuity and ‘‘improved’’ visual acuity
3 Downgraded for imprecision (−1): wide conf idence interval
4 Downgraded for indirectness (−1): outcome was not clearly def ined - ‘‘worsened’’ or ‘‘improved’’ neovascularisat ion
5 Downgraded for imprecision (−2): very wide conf idence interval
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0.5 compared to 0.1 second exposure for proliferative diabetic retinopathy
Patient or population: prolif erat ive diabet ic ret inopathy
Setting: eye hospital
Intervention: 0.5 second exposure
Comparison: 0.1 second exposure
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with 0.1 second
exposure
Risk with 0.5 second
exposure
BCVA: loss of 15 or
more EDTRS letters - 1
year
Study populat ion RR 0.42
(0.08 to 2.04
44
(1 RCT)
⊕⊕©©
LOW 12
200 per 1000 84 per 1000
(16 to 408)
BCVA: gain of 15 or
more EDTRS letters - 1
year
Study populat ion RR 2.22
(0.68 to 7.28)
44
(1 RCT)
⊕⊕©©
LOW 12
150 per 1000 333 per 1000
(102 to 1000)
Progression of PDR - 1
year
Study populat ion RR 0.33
(0.02 to 7.14)
16 (1 RCT) ⊕©©©
VERY LOW 13
125 per 1000 41 per 1000
(3 to 893)
Regression of PDR - 1
year
Study populat ion RR 1.17
(0.92 to 1.48)
32
(1 RCT)
⊕⊕©©
LOW 12
857 per 1000 1000 per 1000
(789 to 1000)
Pain during laser treat-
ment - not reported
- - - - -
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Adverse events Pre-ret inal or vit reous haemorrhage, 30% of 0.
1 sec group, (RR 0.56 (0.18 to 1.70)); macular
thickening, 2 cases in 0.1 sec group; combined
rhegmatous and tract ion ret inal detachment, 1
case in 0.5 sec group
- 44 (1 RCTs) ⊕©©©
VERY LOW 13
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High-certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate-certainty: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low-certainty: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low-certainty: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded for risk of bias (−1): high risk of performance and detect ion bias
2 Downgraded for Imprecision (−1): wide conf idence interval
3Downgraded for Imprecision (−2): small study, very wide conf idence interval
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Light PRP compared to classic PRP for proliferative diabetic retinopathy
Patient or population: prolif erat ive diabet ic ret inopathy
Setting: eye hospital
Intervention: l ight PRP
Comparison: classic PRP
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with classic Risk with Light
BCVA: loss of 15 letters
or more - not reported
- - - - - Mean dif ference in log-
MAR acuity at 1 year
was −0.09, 95% CI −0.
22 to 0.04; part icipants
= 65; studies = 1
BCVA: gain of 15 letters
or more - not reported
Progression of DR - not
reported
- - - - -
Regression of PDR - not
reported
- - - - -
Pain during laser treat-
ment
Study populat ion RR 0.23
(0.03 to 1.93)
65
(1 RCT)
⊕⊕©©
LOW 12
129 per 1000 30 per 1000
(4 to 249)
Adverse events Vitreous haemorrhage, 19% in classic group,
RR 0.07 (0.00 to 1.20); choroidal detachment 3
cases in classic group; neurotrophic keratopa-
thy, 2 cases in classic group; clinically signif i-
- 65 (1 RCTs) ⊕©©©
VERY LOW 13
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cant macular oedema, 23% of classic group, RR
0.13 (0.02 to 1.00)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High-certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate-certainty: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low-certainty: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low-certainty: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded for imprecision (−1): wide conf idence interval
2 Downgraded for risk of bias (−1): high risk of performance and detect ion bias
3 Downgraded for imprecision (−2): few number of events
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Mild scatter PRP compared to full scatter PRP for proliferative diabetic retinopathy
Patient or population: prolif erat ive diabet ic ret inopathy
Setting: eye hospital
Intervention: mild scatter PRP
Comparison: f ull scatter PRP
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with Full scatter
PRP
Risk with M ild scatter
PRP
BCVA: loss of 15 or
more ETDRS letters -
not reported
- - - - - Mean Snellen decimal
acuity was sim ilar in
the two groups at 3
months. M ild scatter 0.
93 (SD 0.11), full scat-
ter 0.89 (SD 0.19)
BCVA: gain of 15 or
more ETDRS letters -
not reported
- - - - -
Progression if PDR - not
reported
- - - - -
Regression of PDR - not
reported
- - - - -
Pain during laser treat-
ment - not reported
- - - - -
Vision-related QoL - not
reported
- - - - -
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Adverse events - not re-
ported
- - - - -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High-certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate-certainty: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low-certainty: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low-certainty: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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Central compared to peripheral for proliferative diabetic retinopathy
Patient or population: prolif erat ive diabet ic ret inopathy
Setting: eye hospital
Intervention: central
Comparison: peripheral
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with peripheral Risk with Central
BCVA: loss of 15 or
more ETDRS letters - 1
year
Study populat ion RR 3.00
(0.67 to 13.46)
50
(1 RCT)
⊕⊕©©
LOW 12
80 per 1000 240 per 1000
(54 to 1000)
BCVA: gain of 15 or
more ETDRS letters - 1
year
Study populat ion RR 0.25 (0.03 to 2.08) 50
(1 RCT)
⊕⊕©©
LOW 12
160 per 1000 40 per 1000
(5 to 333)
Progression of DR - not
reported
-
Regression of PDR - not
reported
- - - - -
Pain during laser treat-
ment - not reported
- - - - -
Vision-related QoL - not
reported
- - - - -
3
0
D
iffe
re
n
t
la
se
rs
a
n
d
te
c
h
n
iq
u
e
s
fo
r
p
ro
life
ra
tiv
e
d
ia
b
e
tic
re
tin
o
p
a
th
y
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Adverse events Vitreous haemorrhage requiring addit ional PRP,
1 case in each group; macular tract ion detach-
ment requiring pars plana vitrectomy, 3 cases in
central group, 1 case in peripheral group; macu-
lar thickening associated with loss of 2 or more
lines of visual acuity, 2 cases in each group
- 50
(1 RCTs)
⊕©©©
VERY LOW 13
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High-certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate-certainty: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low-certainty: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low-certainty: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Dowgraded for risk of bias (−1): high risk of performance and detect ion bias
2 Downgraded for imprecision (−1): wide conf idence interval
3 Downgraded for imprecision (−2): few number of events
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Centre sparing PRP compared to full scatter PRP for proliferative diabetic retinopathy
Patient or population: prolif erat ive diabet ic ret inopathy
Setting: eye hospital
Intervention: centre sparing PRP
Comparison: f ull scatter PRP
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with full scatter
PRP
Risk with Centre spar-
ing
BCVA: loss of 15 or
more ETDRS letters
follow-up: 1 year
Study populat ion RR 0.67
(0.30 to 1.50)
53
(1 RCT)
⊕⊕©©
LOW 12
385 per 1000 258 per 1000
(115 to 577)
BCVA: gain of 15 or
more ETDRS letters fol-
low-up: 1 year - not re-
ported
- - - - -
Progression of DR - not
reported
- - - - -
Regression of PDR
follow up: 1 year
Study populat ion RR 0.96
(0.73 to 1.27)
53
(1 RCT)
⊕⊕©©
LOW 12
808 per 1000 775 per 1000
(590 to 1000)
Pain during laser treat-
ment - not reported
- - - - -
Vision-related QoL - not
reported
- - - - -
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Adverse events - not re-
ported
- - - - -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High-certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate-certainty: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low-certainty: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low-certainty: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded for risk of bias (−1): high risk of performance and detect ion bias
2 Downgraded for imprecision (−1): wide conf idence intervals
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Extended targeted PRP compared with standard PRP for proliferative diabetic retinopathy
Patient or population: people with diabet ic ret inopathy
Settings: eye hospital
Intervention: extended targeted PRP
Comparison: standard PRP
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
standard PRP extended targeted PRP
BCVA: loss of 15 or
more ETDRS letters: fol-
low-up 1 year
Study populat ion RR 0.94
(0.70 to 1.28)
270 (1 RCT) ⊕⊕©©
LOW12
Mean dif ference in
BCVA at 1 year was: 0.
00 logMAR, (−0.05 to
0.05)
393 per 1000 369 per 1000
(275 to 503)
BCVA: gain of 15 or
more ETDRS letters: fol-
low-up 1 year, not re-
ported
- - - - - -
Progression of DR - not
reported
- - - - - -
Regression of PDR
follow-up 1 year
Study populat ion RR 1.11
(0.95 to 1.31)
270
(1 RCT)
⊕⊕©©
LOW12
644 per 1000 715 per 1000
(612 to 844)
Pain during laser treat-
ment - not reported
- - - - - -
Vision-related QoL - not
reported
- - - - - -
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Adverse events Quote: ‘‘None of the eyes developed tract ional ret inal detachment during the study. Addit ionally,
no ocular or non-ocular AEs related to the study intervent ion were detected by the invest igators or
reported by pat ients’’
⊕©©©
VERY LOW 3
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk Ratio; AE: adverse events
GRADE Working Group grades of evidence
High-certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate-certainty: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low-certainty: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low-certainty: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded for risk of bias (−1): high risk of performance and detect ion bias
2 Downgraded for imprecision (−1): wide conf idence intervals
3 Downgraded for imprecision (−3): study was underpowered to detect rare adverse ef fects.
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D I S C U S S I O N
Summary of main results
There is recent interest in alternative laser photocoagulation strate-
gies to the one used by the ETDRS in the treatment of PDR, using
other lasers and different treatment approaches with, for example,
less intense laser burns or more targeted laser strategies. We re-
viewed relevant studies with the aim to determine whether these
new proposed treatment modalities are equally or more effective
with potentially fewer side effects.
We identified 11 RCTs which compared alternative laser strate-
gies for the treatment of PDR with standard argon laser PRP as
performed in the ETDRS. We defined the comparator “standard
argon laser PRP” as single spot treatment according to ETDRS
guidelines. Specifically, the recommendations in the ETDRS were
an initial treatment with peripheral scatter laser treatment con-
sisting of 1200 to 1600 burns of moderate intensity, 200 µm to
500 µm spot size, with one-half to one-spot diameter spacing and
duration of 100 ms to 200 ms, and power titrated to produce
moderate-intensity burns but with full treatment divided over at
least two sessions according to different clinical scenarios (ETDRS
Research Group 1987).
Five studies compared different lasers with standard argon laser
PRP: two frequency double Nd:YAG (Bandello 1996; Brancato
1991); and three diode laser (Bandello 1993; Han 1995; Tewari
2000). One study evaluated a longer duration of laser pulse (0.5
second versus 0.1 second) (Wade 1990). One study compared a
’light intensity’ lower energy argon laser PRP treatment to achieve
a very light grey biomicroscopic effect on the retina versus ’classic’
argon laser PRP to achieve an opaque, dusky, grey-white, off-white
standard burn (Bandello 2001).One study compared ’mild scatter’
argon laser PRP with pattern limited to 400 to 600 laser burns
(500 µm, 0.1 sec) over one session versus ’full scatter’ argon laser
PRP with 1200 to 1600 laser burns (500 µm, 0.1 sec) over two
sessions, two weeks apart (Pahor 1998).
Two studies compared different distribution of areas treated versus
standard PRP. The first study compared ’central’ versus ’periph-
eral’ argon laser PRP treatment (Blankenship 1988). In this study
argon laser PRP targeted the midperipheral fundus with the num-
ber of burns ranging from 410 to 500, but in addition the ’cen-
tral’ PRP group had burns (ranging in number from 400 to 470)
more posteriorly, sparing a 2 DD area centred on the fovea, and
papillomacular bundle. The ’peripheral’ PRP (ranging from 400
to 500) placed burns more peripherally, anterior to the equator
extending to the ora serrata. The second study compared ’centre
sparing’ versus ’full scatter’ argon PRP (Theodossiadis 1990). This
study used argon laser PRP burns (1500 to 3000 burns of 200 µm
to 500 µm diameter) in two groups. In Group A ’centre sparing’
argon laser PRP covered the entire retinal periphery and midpe-
riphery beginning 1 DD from the pars plana, but the posterior
pole was spared a 2 DD area centred on the fovea and including
the papillomacular bundle. In Group B ’full scatter’ argon laser
PRP involved the periphery and midperiphery but stopped 1 DD
short of the nasal margins of the optic disc and 3 DD away from
the upper, lower and temporal margins of the fovea.
One study compared the ’extended targeted’ argon laser PRP
(ETRP) treatment of ischaemic areas of the retina versus ’standard’
conventional PRP (CPRP) (Nikkhah 2017). Treatment in both
arms applied 1200 to 1600 argon laser burns with spot size of
200 µm, duration 200 ms and spacing of 0.5 burn width. In the
ETRP group the laser was applied to the entire retina anterior to
the equator as well as the capillary non-perfusion areas between
the vascular arcade and the equator. CPRP laser was applied from
the vascular arcade toward the midperiphery.
Overall completeness and applicability of
evidence
There was no difference in the population included in these stud-
ies. All studies looked at both male and female adults with a clin-
ical diagnosis of type 1 or type 2 diabetes mellitus, between the
age of 18 to 79 years of age. One or both eyes of each participant
were required to have high risk PDR.
Although all studies reported our primary outcome the research
question was not fully answered as there were fewRCTs for each of
the comparisons (at most three studies), they were small in size (9
of the 11 studies included 50 participants or fewer) and with high
risk of bias. None of the included RCTs reported the following
outcomes of interest: near visual acuity; patient-relevant outcomes
such as loss of driving licence; vision-related QoL measures. No
details of any resource or cost implications were provided. Visual
field loss was only reported in one study and pain during treatment
was reported in three studies.
Recent developments in laser treatment of PDR include semi-au-
tomated patterned scanning laser, with rapid application of mul-
tiple laser spots in an array with shorter pulse duration of 10 ms
to 30 ms. We were unable to confirm if there are advantages of
multispot laser over conventional argon laser PRP as no trial met
our inclusion criteria of using standard argon laser PRP as a com-
parator. Of note: the two-year results of the DRCR.net protocol
reported outcomes of a subgroup of diabetic patients with PDR
and treated with laser PRP receiving single spot or pattern laser
treatments but as allocation to pattern or single-spot laser was not
randomised we could not include it in our review (Bressler 2017).
Navigated laser is another multispot laser modality with fundus
imaging that utilises retinal navigation via computerized image
capture and tracking assistance with high precision and repro-
ducibility. No studies were identified that compared multispot
laser with conventional argon laser.
Quality of the evidence
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The evidence from the studies included in our review was mostly
graded as low- or very low-certainty.
The studies were poorly conducted and poorly reported and were
judged to be at high risk of bias in at least one domain. All but one
of the included studies included more than one eye per person but
none of these studies adjusted for within-person correlation.
The studies were small: the size varied from 20 to 270 eyes. The
majority of studies included 50 or fewer particpants, with only
two studies including more: 104 participants (Han 1995); and
234 participants (Nikkhah 2017). As a result the effect estimates
were imprecise. We also downgraded for indirectness as some of
the outcomes were not defined clearly and did not correspond
directly to our review outcomes.
Potential biases in the review process
We followed standard methods expected by Cochrane. We have
documented all departures from the protocol in Differences
between protocol and review.
Agreements and disagreements with other
studies or reviews
The ETDRS recommended multi-session PRP laser extending
into the midperipheral zones in high-risk eyes (RCOphth Level
1) (DRS Research Group 1981). The current clinical Diabetic
Retinopathy guidelines of the UKRoyal College of Ophthalmolo-
gists state that PRP is recommended in high-risk PDR (RCOphth
Diabetic Retinopathy Guidelines 2012). It is recommended that
“as retinopathy approaches the proliferative stage, laser scatter
treatment (PRP) should be increasingly considered to prevent pro-
gression to high risk PDR”. However the preface to these Col-
lege recommendations highlights that “technological advances in
new laser technology usingmultispot andmicropulse abilities have
widened clinical knowledge and treatment options”. Our review
was unable to find evidence to definitively support alternative
modalities of treatment.
AnNIHRhealth technology assessment evaluated the effectiveness
and safety of laser PRP for people with pre-PDR. This cohort was
not included in our review but it is interesting to note that they
found the current evidence is insufficient to recommend PRP for
severe NPDR and that there was no robust evidence to determine
whether new, more modern laser systems are more effective than
the standard argon laser used in ETDRS although they appear to
have fewer adverse effects (Royle 2015).
There has been interest in the use of anti-VEGF for treatment
of PDR. The Diabetic Retinopathy Clinical Research Network
(DRCR.net protocol S 2015) was a non-inferiority study to de-
termine if intravitreal ranibizumab was non-inferior to PRP for
treatment of high-risk PDR. The study authors concluded that
treatment with intravitreal ranibizumab resulted in visual acuity
that was non-inferior to PRP at two years. CLARITY is a phase
2b, single-masked, non-inferiority multicentre trial of 232 partic-
ipants with PDR and found that those treated with intravitreal
Aflibercept had an improvedBCVAoutcome at one year compared
with those treated with PRP standard care (CLARITY 2017). An-
other randomised clinical trial comparing ranibizumab and PRP
reported two-year outcomes in high-risk PDR with and without
macular oedema and showed ranibizumab monotherapy is non-
inferior to PRP, with less visual field loss and incident vitrectomy
(Gross 2015).
However it is important to note that both the DRCR.net protocol
S and CLARITY studies included diabetic participants predomi-
nantly without high-risk characteristics (HRC) of PDR. This has
implications in drawing clinically useful conclusions as short term
there may be benefit in the use of anti-VEGF therapy when only
the side effects of the laser are seen. People without HRC may
have remained stable with or without treatment. Only longer term
outcomes of treatment targeting this group of people will quantify
fully the efficacy, risk:benefit ratio and the long-term compliance
of patients.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Modern laser techniques and modalities have been developed to
treat PDR. However there is an evidence gap with respect to the
efficacy and safety of alternative laser systems or strategies com-
pared with the standard argon laser as described in ETDRS.
Implications for research
Sight loss due to DR has already been identified as a public health
priority by the Royal National Institute of Blind People (RNIB
2009) and as a research priority by the James Lind Alliance (“How
can sight loss from diabetic retinal changes be prevented and re-
duced?”) (Rowe 2014).
Evaluating the most effective laser PRP treatment for PDR with
least side effects is an important question. In particular larger high-
quality studies are needed to look at the benefits of newer lasers and
techniques compared with conventional argon laser PRP for all
outcomes, and in particular the long term outcomes most relevant
to patients.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bandello 1993
Methods Study design: randomised controlled trial
Study grouping: parallel group
Participants Baseline characteristics
Diode laser
• Number of people (eyes) randomised: 17 (22)
• Number (%) of people followed up: 17 (100%)
• Average age in years: 54
• Age range in years: NR
• Percentage women: 29%
• Ethnic group: NR
• Percentage type I diabetes: 66%
• Percentage type II diabetes: 34%
• Mean baseline visual acuity (SD): 0.7 (0.3)
Argon-green laser
• Number of people (eyes) randomised: 17 (22)
• Number (%) of people followed up: 17 (100%)
• Average age in years: 44
• Age range in years: NR
• Percentage women: 41%
• Ethnic group: NR
• Percentage type I diabetes: 41%
• Percentage type II diabetes: 59%
• Mean baseline visual acuity (SD): 0.7 (0.2)
Overall
• Number of people (eyes) randomised: 34 (44)
• Number (%) of people followed up: 34 (100%)
• Average age in years: 49
• Age range in years: NR
• Percentage women: 35%
• Ethnic group:
• Percentage type I diabetes:
• Percentage type II diabetes:
• Mean baseline visual acuity (SD):
Inclusion criteria: age at least 18 years; visual acuity (VA) of 0.3 or more;
PDR with clinically obvious disc new vessels or neovascularisations elsewhere along
the vascular arcades (equal to or more than one-half the disc area or associated with
hemorrhage)
Exclusion criteria: vitreous hemorrhage obscuring more than 25 % of the fundus,
maculopathy reducing the VA to below 0.3, tractional retinal detachment,
Pretreatment: Possible differences in demographics, type of diabetes and duration of
disease (Table 1). No statistical analysis on differences
Eyes: 44 eyes of 34 people with 10 people having a within-person design. No adjustment
made in the analysis
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Interventions Intervention characteristics
Diode laser
• Type of laser: diode laser (810nm)
• Total number of burns: 2335 (SD 703)
• Number of laser sessions: 10
• Laser application (single/multispot): single
• Laser route (slit lamp/fundus camera): slit lamp
• Laser target location (panretinal/ischaemia targeted): ablation of nonperfused
peripheral and midperipheral retinal areas
• Any additional therapy (non-PDR related):
• Mean laser power and size: 752 (SD 113) mW, 500 microns. Power decreased to
670 (SD 90) mW after the first 13 cases.
Argon-green laser
• Type of laser: argon laser
• Total number of burns: 2041 (SD 305)
• Number of laser sessions: 5
• Laser application (single/multispot): single
• Laser route (slit lamp/fundus camera): slit lamp
• Laser target location (panretinal/ischaemia targeted):
• Any additional therapy (non-PDR related): ablation of nonperfused peripheral
and midperipheral retinal areas
• Mean laser power and size: 432 (SD 116) mW, 500 microns
Outcomes Visual acuity, PDR regression, vitreous haemorrhage, choroidal detachment, pain, com-
plications
Follow-up: mean follow-up 24 (SD 4) months in the diode laser group and 25 (SD 5)
months in argon laser group
Notes Funding: NR
Declaration: NR
Country: Italy
Setting: eye hospital
Date of study: November 1989 to July 1990
Contacting of study investigator: not contacted
Trial registration number: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote “Randomization assigned consecu-
tively one eye to ALT and the next to DLT.
Of the ten patients in which both eyes were
included in the study, the right eye was as-
signed to DLT and the left to DLT”
Judgement comment: Assignment appears
to be by alternation.
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Allocation concealment (selection bias) High risk Judgement comment: Allocation was not
concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: no information on
masking. We assume that in absence of re-
porting on this, participants and personnel
were not masked
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement comment: no information on
masking. We assume that in absence of re-
porting on this, outcome assessors were not
masked
Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement comment: no apparent loss to
follow-up
Selective reporting (reporting bias) Unclear risk Judgement comment: no access to protocol
or trials registry entry
Bandello 1996
Methods Study design: randomised controlled trial
Study grouping: parallel group
Participants Baseline characteristics
Nd:YAG laser
• Number of people (eyes) randomised: NR (NR)
• Number (%) of people followed up: 21 eyes (NR)
• Average age in years: 45
• Age range in years: NR
• Percentage women: NR
• Ethnic group: NR
• Percentage type I diabetes: NR
• Percentage type II diabetes: NR
• Mean baseline visual acuity (SD): 0.69 (0.23) Snellen decimal acuity
Argon-green laser
• Number of people (eyes) randomised: NR (NR)
• Number (%) of people followed up: 21 eyes (NR)
• Average age in years: 44
• Age range in years: NR
• Percentage women: NR
• Ethnic group: NR
• Percentage type I diabetes: NR
• Percentage type II diabetes: NR
• Mean baseline visual acuity (SD): 0.66 (0.22) Snellen decimal acuity
Overall
• Number of people (eyes) randomised: NR (NR)
• Number (%) of people followed up: 33 people 42 eyes (NR)
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• Average age in years: 44
• Age range in years: NR
• Percentage women: 42%
• Ethnic group: NR
• Percentage type I diabetes: 82% insulin dependent
• Percentage type II diabetes: NR
• Mean baseline visual acuity (SD): 0.66 (0.22) Snellen decimal acuity
Inclusion criteria: age at least 18 years, visual acuity of 0.3 or more; PDR with clinically
obvious disc new vessels, or neovascularisation elsewhere along the vascular arcades (equal
to or more than 1/2 disc area or associated with haemorrhage)
Exclusion criteria: lens opacities and/or vitreous haemorrhages obscuring the fundus;
maculopathy reducing visual acuity below 0.3; tractional retinal detachment; previous
laser treatment
Pretreatment: groups balanced with respect to age, type of diabetes and diabetes dura-
tion. More men in argon group but difficult to tell because of discrepancies in numbers
and lack of information on denominators in terms of people rather than eyes
Eyes: a mixture of one and both eyes per person (42 eyes of 33 people). When both eyes
were eligible (9 out of 33 participants) the laser selection was not random
Interventions Intervention characteristics
Nd:YAG laser
• Type of laser: double-frequency Nd:YAG (532 nm)
• Total number of burns: 1642
• Number of laser sessions: 6
• Laser application (single/multispot): single
• Laser route (slit lamp/fundus camera): slit lamp
• Laser target location (panretinal/ischaemia targeted): ablation of non-perfused
peripheral and midperipheral retinal areas, avoiding the areas inside the temporal
vascular arcades.
• Any additional therapy (non-PDR related): NR
• Mean laser power and size: Power: 65 mW k 63
Argon-green laser
• Type of laser: 920 Argon Coherent Medical (Coherent, Palo Alto, CA) and an
Argon Ophtalas (Biophysics Medical, Clermont Ferrand, France) and NdLT by a
Crystal Focus-Emerald Laser (Biovision, Cournon d’Avergne, France)
• Total number of burns: 1807
• Number of laser sessions: 5.3
• Laser application (single/multispot): single (500 µm site of burn)
• Laser route (slit lamp/fundus camera): slit lamp
• Laser target location (panretinal/ischaemia targeted): pan
• Any additional therapy (non-PDR related): NR
• Mean laser power and size: Size 500 µm - The mean laser power used in ALT was
484 mW k 78
Outcomes Best corrected visual acuity (Snellen decimal acuity); retinopathy by fundus photographs
and panretinal fluorescein angiography
Follow-up: 30 months
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Notes Funding: NR
Declaration: NR
Country: Italy
Setting: eye hospital
Date of study: December 1990 to April 1992
Contacting of study investigator: not contacted
Trial registration number: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: not reported how list
was generated. Trial was described as “ran-
domised” but with no further details
Allocation concealment (selection bias) Unclear risk Judgement comment: not reported how al-
location was administered. Trial was de-
scribed as “randomised” but with no fur-
ther details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: no information on
masking. We assume that in absence of re-
porting on this, participants and personnel
were not masked
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement comment: no information on
masking. We assume that in absence of re-
porting on this, outcome assessors were not
masked
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “In the ALT group one eye was ex-
cluded from the study after 28 months of
follow-up because of the development of a
cataract, which made visualization of the
fundus difficult and greatly reduced visual
acuity. In the NdLT group one eye had to
be excluded after 22 months of follow-up
because of central retinal artery occlusion”
Selective reporting (reporting bias) Unclear risk Judgement comment: no access to protocol
or trials registry entry
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Methods Study design: randomised controlled trial
Study grouping: parallel group
Participants Baseline characteristics
Intervention
• Number of people (eyes) randomised: 26 (34 eyes)
• Number (%) of people followed up: NR
• Average age in years: 48
• Age range in years: NR
• Percentage women: 39%
• Ethnic group: NR
• Percentage type I diabetes: 54% insulin dependent
• Percentage type II diabetes: NR
• Mean baseline visual acuity (SD): 0.12 (0.13) logMAR acuity
Comparator
• Number of people (eyes) randomised: 24 (31 eyes)
• Number (%) of people followed up: NR
• Average age in years: 57
• Age range in years: NR
• Percentage women: 38%
• Ethnic group: NR
• Percentage type I diabetes: 42% insulin dependent
• Percentage type II diabetes: NR
• Mean baseline visual acuity (SD): 0.14 (0.15) logMAR acuity
Overall
• Number of people (eyes) randomised: 50 (65 eyes)
• Number (%) of people followed up: 100%
• Average age in years: 52
• Age range in years: NR
• Percentage women: 38%
• Ethnic group: NR
• Percentage type I diabetes: 48% insulin dependent
• Percentage type II diabetes: NR
• Mean baseline visual acuity (SD): 0.13 (NR) logMAR acuity
Inclusion criteria: age at least 18 years; BCVA of 0.4 or more; PDR with 2 to 4 high-
risk characteristics (new vessels at disk greater than 1/4 to 1/3 disc area or vitreous or
pre-retinal haemorrhage associated with less extensive new vessels at disk, or with new
vessels elsewhere 1/2 disc area or more in size)
Exclusion criteria: vitreous haemorrhage obscuring more than 20% of the fundus;
maculopathy reducing the BCVA to below 0.4; tractional retinal detachment; media
clarity inadequate to permit completion of laser PRP; previous laser treatment
Pretreatment: classic PRP group a bit older (average age 57 versus 48); a bit more insulin
dependent diabetes in light PRP group; more CSME in classic PRP group
Eyes: a mixture of one eye per person and within-person study. 65 eyes of 50 people.
Quote: “Of the 15 patients in which both eyes were included in the study, the right eye
was randomly assigned to one of the two treatment techniques and the left eye to the
other”
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Interventions Intervention characteristics
Intervention
• Type of laser: argon (light)
• Total number of burns: mean 2748 (SD 468)
• Number of laser sessions: mean 3.5 (SD 1.3)
• Laser application (single/multispot): single
• Laser route (slit lamp/fundus camera): slit lamp
• Laser target location (panretinal/ischaemia targeted): Panretinal but focal if CSME
• Any additional therapy (non-PDR related): in eyes selected for light PRP, the
operator tried to obtain a very light grey biomicroscopic effect on the retina (Fig. 1).
The energy employed was the lowest capable of producing a result on the retinal tissue.
The target corresponded to the Grade 1 of L’Esperance scale (barely visible, blanching
of pigment epithelium).
Comparator
• Type of laser: argon (classic)
• Total number of burns: mean 2080 (SD 320)
• Number of laser sessions: mean 8.7 (SD 2.1)
• Laser application (single/multispot): single
• Laser route (slit lamp/fundus camera): slit lamp
• Laser target location (panretinal/ischaemia targeted): panretinal but focal if CSME
• Any additional therapy (non-PDR related): In eyes selected for classic PRP, the
treatment target was the classic burn (Fig. 2) corresponding to grade 3 of L’Esperance
scale (opaque, dusky, grey-white,off-white). When the high-risk characteristics
remained unchanged, further treatments were performed using the same technique.
Outcomes Best corrected logMAR acuity, progression and regression, macular oedema, pain and
complications, visual fields
Follow-up: 22 months
Notes Funding: NR
Declaration of interest: NR
Country: Italy
Setting: eye hospital
Date study conducted: November 1995 to October 1996
Trial registration number: NR
Contacting study investigators: not contacted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Judgement comment: Quote: “Random-
ization assigned eyes either to light or to
classic PRP on the basis of computer-gen-
erated random numbers.”
Allocation concealment (selection bias) Unclear risk Judgement comment: not reported how al-
location administered. Trial was described
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as “randomised” but with no further details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: no information on
masking. We assume that in absence of re-
porting on this, particpants and personnel
were not masked
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement comment: no information on
masking. We assume that in absence of re-
porting on this, outcome assessors were not
masked
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: follow-up not re-
ported.
Selective reporting (reporting bias) Unclear risk Judgement comment: no access to protocol
or trials registry entry
Blankenship 1988
Methods Study design: randomised controlled trial
Study grouping: parallel group
Participants Baseline Characteristics
Intervention
• Number of people (eyes) randomised: 24 (25 eyes)
• Number (%) of people followed up: 25 eyes (100%)
• Average age in years: 40
• Age range in years: 19 to 65
• Percentage women: 58%
• Ethnic group: NR
• Percentage type I diabetes: 92% maintained with insulin
• Percentage type II diabetes: NR
• Mean baseline visual acuity (SD): NR
Comparator
• Number of people (eyes) randomised: 24 (25 eyes)
• Number (%) of people followed up: 25 eyes(100%)
• Average age in years: 46
• Age range in years: 23 to 69
• Percentage women: 50%
• Ethnic group: NR
• Percentage type I diabetes: 80% maintained with insulin
• Percentage type II diabetes: NR
• Mean baseline visual acuity (SD): NR
Overall
• Number of people (eyes) randomised: 40 (50 eyes)
• Number (%) of people followed up: 100%
• Average age in years: 43
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• Age range in years: 19 to 69
• Percentage women: 54
• Ethnic group: NR
• Percentage type I diabetes: 85% maintained with insulin
• Percentage type II diabetes: NR
• Mean baseline visual acuity (SD): NR
Inclusion criteria: diabetes mellitus; available for follow-up; 6/30 or better BCVA; 3
or 4 diabetic retinopathy risk factors; media clarity to permit argon laser PRP within a
single session
Exclusion criteria: prior photocoagulation; substantial lens opacities or vitreous haem-
orrhages sufficient to prevent complete argon laser PRP
Pretreatment: groups were similar.
Eyes: Both eyes were enrolled in 10 people (50 eyes of 40 people); both eyes reported but
not adjusted for within-person correlation. In comparator group 1 eye not randomised
to make both arms equal
Interventions Intervention characteristics
Intervention
• Type of laser: central argon PRP laser
• Total number of burns: 452 midperiphery + 437 posteriorly (mean n)
• Number of laser sessions: 1
• Laser application (single/multispot): single
• Laser route (slit lamp/fundus camera): slit lamp
• Laser target location (panretinal/ischaemia targeted): panretinal
• Any additional therapy (non-PDR related): no post-treatment medications
• Spot size (µm): 500
• Laser burn intensity (light/moderate/heavy): moderate blanching
• Laser burn spacing: NR
• Any additional information on intervention/comparator: retrobulbar anaesthesia
used for all cases as per protocol.
Comparator
• Type of laser: peripheral argon PRP laser
• Total number of burns: 446 midperiphery + 441 more peripherally (mean n)
• Number of laser sessions: 1
• Laser application (single/multispot): single
• Laser route (slit lamp/fundus camera): slit lamp
• Laser target location (panretinal/ischaemia targeted): panretinal
• Any additional therapy (non-PDR related): no post treatment medications
• Spot size (µm): 500
• Laser burn intensity (light/moderate/heavy): moderate blanching
• Laser burn spacing: NR
• Any additional information on intervention/comparator: retrobulbar anaesthesia
Outcomes Best corrected visual acuity (Snellen lines) visual fields scores; macular thickening; neo-
vascularisation of the disc and retina; intraocular pressure; vitreous haemorrhage
Follow-up: 6 months
Notes Funding: “Supported in part by patients and contributors of the Bascom Palmer Eye
Institute, Research to Prevent Blindness. Inc, New York, the Florida Lions Eye Bank,
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and the Brenn Green Diabetic Retinopathy Fund, Miami, Florida.”
Declaration of interest: NR
Country: USA
Setting: eye hospital
Date study conducted: NR
Trial registration number: not reported
Contacting study investigators: not contacted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “After the patient had been in-
formed and had consented to partici-
pate, a coin was flipped which determined
whether the eye was to receive central or
peripheral PRP argon laser treatment. The
last two eyes were not Randomised but re-
ceived central PRP treatment to make an
equal number of 25 eyes in each group.”
Allocation concealment (selection bias) Low risk Quote: “a coin was flipped which deter-
mined whether the eye was to receive cen-
tral or peripheral PRP argon laser treat-
ment. The last two eyes were not Ran-
domised but received central PRP treat-
ment to make an equal number of 25 eyes
in each group.”
Judgement comment: allocation decided
after informed and agreed to participate
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: no information on
masking. We assume that in the absence of
reporting on this, participants and person-
nel were not masked
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement comment: no information on
masking. We assume that in the absence of
reporting on this, participants and person-
nel were not masked
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “All of the patients returned for fol-
low-up evaluations 6 months after treat-
ment.”
Judgement comment: 1- and 6-month fol-
low-up available for all participants
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Selective reporting (reporting bias) Unclear risk Judgement comment: no access to protocol
or trial register entry
Brancato 1991
Methods Study design: randomised controlled trial
Study grouping: parallel group
Participants Baseline Characteristics
Intervention
• Number of people (eyes) randomised: 8 (10 eyes)
• Number (%) of people followed up: 100%
• Average age in years: 45
• Age range in years: NR
• Percentage women: 40%
• Ethnic group: NR
• Percentage type I diabetes: 30%
• Percentage type II diabetes: 70%
• Mean baseline visual acuity (SD): 0.67 (0.24) Snellen decimal acuity
Comparator
• Number of people (eyes) randomised: 8 (10 eyes)
• Number (%) of people followed up: 100%
• Average age in years: 43
• Age range in years: NR
• Percentage women: 30%
• Ethnic group: NR
• Percentage type I diabetes: 30%
• Percentage type II diabetes: 70%
• Mean baseline visual acuity (SD): 0.60 (0.23) Snellen decimal acuity
Overall
• Number of people (eyes) randomised: 16 (20 eyes)
• Number (%) of people followed up: 100%
• Average age in years: 44
• Age range in years: NR
• Percentage women: NR
• Ethnic group: NR
• Percentage type I diabetes: 30%
• Percentage type II diabetes: 70%
• Mean baseline visual acuity (SD): 0.64 (NR) Snellen decimal acuity
Inclusion criteria: age at least 18 years; visual acuity ≥ 0.3; PDR with clinical obvious
new vessels on disc or with new vessels elsewhere along vascular arcades, equal to and/or
more than 1 disc area or associated with haemorrhage
Exclusion criteria: Opacities of the lens and/or vitreous haemorrhage which would raise
difficulties when performing PRP; tractional retinal detachment; previous laser treatment
Pretreatment: NR: “After randomization, the two groups of patients were found to have
comparable clinical characteristics such as age, sex, type and duration of diabetes mellitus
and IVA”
Eyes: 20 eyes of 16 people
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Interventions Intervention characteristics
Intervention
• Type of laser: frequency-doubled Nd:YAG laser (532 nm)
• Total number of burns: 1958 (mean), 256 (SD)
• Number of laser sessions: 5.87 (mean) 0.57 (SD)
• Laser application (single/multispot): not clearly stated but most likely single
• Laser route (slit lamp/fundus camera): slit lamp
• Laser target location (panretinal/ischaemia targeted): PRP but targeting
specifically areas of non-perfusion in midperipheral and peripheral retina
• Any additional therapy (non-PDR related): no
• Spot size (µm): 500 µm
• Laser burn intensity (light/moderate/heavy): no info given
• Laser burn spacing: no info given
• Any additional information on intervention/comparator: none
Comparator
• Type of laser: argon-green laser (514 nm)
• Total number of burns: 2037 (mean) 302.3 (SD)
• Number of laser sessions: 4.78 (mean) 0.81 (SD)
• Laser application (single/multispot): not stated but should be single
• Laser route (slit lamp/fundus camera): slit lamp
• Laser target location (panretinal/ischaemia targeted): PRP but targeting
specifically areas of non-perfusion in midperipheral and peripheral retina
• Any additional therapy (non-PDR related): no
• Spot size (µm): 500 µm
• Laser burn intensity (light/moderate/heavy): no info given
• Laser burn spacing: no info given
• Any additional information on intervention/comparator: no
Outcomes Visual acuity (Snellen); new vessel regression; side effects including pain; vitreous haem-
orrhage; and choroidal detachment
Follow-up: 6 months
Notes Funding: NR
Declaration: NR
Country: Italy
Setting: eye hospital
Date study conducted: NR
Trial registration number: NR
Contacting study investigators: not contacted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: no info on how the
sequence generation list was done
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Allocation concealment (selection bias) Unclear risk Judgement comment: no information pro-
vided on allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: no information on
masking. We assume that in absence of re-
porting on this, participants and personnel
were not masked
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No information on masking. We assume
that in absence of reporting on this, partic-
ipants and personnel were not masked
Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement comment: it appears that they
provide data for all participants in all out-
comes (visual acuity and retinopathy) sta-
tus - although they do not list the outcomes
nor say which one is the primary outcome
and which one secondary outcome
Selective reporting (reporting bias) Unclear risk No access to trial protocol or registry entry
Han 1995
Methods Study design: randomised controlled trial
Study grouping: parallel group
Participants Baseline Characteristics
Intervention
• Number of people (eyes) randomised: 50 (50 eyes)
• Number (%) of people followed up: 100%
• Average age in years: 56
• Age range in years: 27 to 67
• Percentage women: 44%
• Ethnic group: South Korean
• Percentage type I diabetes: NR
• Percentage type II diabetes: NR
• Mean baseline visual acuity (SD): NR
Comparator
• Number of people (eyes) randomised: 58 (58 eyes)
• Number (%) of people followed up: 100%
• Average age in years: 52
• Age range in years: 36 to 73
• Percentage women: 43%
• Ethnic group: South Korean
• Percentage type I diabetes: NR
• Percentage type II diabetes: NR
• Mean baseline visual acuity (SD): NR
Overall
57Different lasers and techniques for proliferative diabetic retinopathy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Han 1995 (Continued)
• Number of people (eyes) randomised: 108 (108 eyes)
• Number (%) of people followed up: 108 (100%)
• Average age in years: 54
• Age range in years: 22 to 73
• Percentage women: 44%
• Ethnic group: South Korean
• Percentage type I diabetes: NR
• Percentage type II diabetes: NR
• Mean baseline visual acuity (SD): NR
Inclusion criteria: Admitted into the Pusan University Hospital with a diagnosis of
diabetic retinopathy
Exclusion criteria: more than ¼ of their eyes covered with blood due to vitreous haem-
orrhage after treatment; visual acuity below 0.3 due to diabetic maculopathy, as recorded
before or after treatment; traction retinal detachment before or after treatment
Pretreatment: “Patients diagnosed with diabetic retinopathy (preproliferative or prolif-
erative)”. The mean ages and gender ratio of groups were comparable; however, no ad-
ditional information about participants in the group such as stage of disease is provided
Eyes: unclear
Interventions Intervention Characteristics
Intervention
• Type of laser: diode
• Total number of burns: mean 3051
• Number of laser sessions: mean 6.2
• Laser application (single/multispot): NR
• Laser route (slit lamp/fundus camera): NR (most likely slit lamp)
• Laser target location (panretinal/ischaemia targeted): PRP
• Any additional therapy (non-PDR related): none
• Spot size (µm): 200 to 500
• Laser burn intensity (light/moderate/heavy): NR
• Laser burn spacing: NR
• Any additional information on intervention/comparator: none
Comparator
• Type of laser: argon
• Total number of burns: mean 2067
• Number of laser sessions: mean 4.8
• Laser application (single/multispot): NR
• Laser route (slit lamp/fundus camera): NR (most likely slit lamp)
• Laser target location (panretinal/ischaemia targeted): PRP
• Any additional therapy (non-PDR related): none
• Spot size (µm): 200 to 400
• Laser burn intensity (light/moderate/heavy): NR
• Laser burn spacing: NR
• Any additional information on intervention/comparator: it seems that participants
in the argon laser group were further divided into the argon-green group or argon blue-
green group. However, results were not given for each of these groups separately.
Outcomes Diabetic neovascular changes; visual acuity; complications including pain; vitreous haem-
orrhage; maculopathy; cataract; pre-retinal membrane
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Follow-up: 13 to 15 months.
Notes Funding: NR
Declaration of interest: NR
Country: South Korea
Setting: eye Hospital
Date study conducted: May 1978 to August 1993
Trial registration number: NR
Contacting study investigators: not contacted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: not reported how list
was generated. Trial was described as “ran-
domised” but with no further details
Allocation concealment (selection bias) Unclear risk Judgement comment: not reported how list
was generated. Trial was described as “ran-
domised” but with no further details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: study was probably
not masked.
No information on masking. We assume
that in absence of reporting on this, partic-
ipants and personnel were not masked
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement comment: study was probably
not masked.
No information on masking. We assume
that in absence of reporting on this, partic-
ipants and personnel were not masked
Incomplete outcome data (attrition bias)
All outcomes
High risk Judgement comment: the number of par-
ticipants randomised matched the number
of participants analysed. Loss to follow-up
not clearly reported. In exclusion criteria
some indication that people with adverse
events excluded after treatment but not re-
ported howmany this applied to: exclusion
criteria “more than ¼ of their eyes covered
with blood due to vitreous haemorrhage af-
ter treatment; visual acuity below0.3due to
diabeticmaculopathy, as recorded before or
after treatmentwere excluded; traction reti-
nal detachment before or after treatment”
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Selective reporting (reporting bias) Unclear risk Judgement comment: no access to protocol
or trials registry entry
Nikkhah 2017
Methods Study design: randomised controlled trial
Study grouping: parallel group
Participants Baseline characteristics
Extended targeted retinal photocoagulation
• Number of people (eyes) randomised: NR (143 eyes)
• Number (%) of people followed up: 135 eyes (95%)
• Average age in years: 50
• Age range in years: 21 to 67
• Percentage women: 46%
• Ethnic group: NR
• Percentage type I diabetes: NR
• Percentage type II diabetes: NR
• Mean baseline visual acuity (SD): 0.38 (0.26) logMAR acuity
Conventional PRP
• Number of people (eyes) randomised: NR (142 eyes)
• Number (%) of people followed up: 135 eyes (95%)
• Average age in years: 50
• Age range in years: 23 to 69
• Percentage women: 50%
• Ethnic group: NR
• Percentage type I diabetes: NR
• Percentage type II diabetes: NR
• Mean baseline visual acuity (SD): 0.4 (0.27) logMAR acuity
Overall
• Number of people (eyes) randomised: 249 (285 eyes)
• Number (%) of people followed up: 234 (94%) 270 eyes
• Average age in years: 50
• Age range in years: 21 to 69
• Percentage women: 48%
• Ethnic group: NR
• Percentage type I diabetes: NR
• Percentage type II diabetes: NR
• Mean baseline visual acuity (SD): 0.38 (0.2) logMAR acuity
Inclusion criteria: early or high-risk PDR based on DRS definition
Exclusion criteria: prior retinal laser treatment to the study eye; CMT of more than
300 µm as measured by OCT or the presence of sub- or intraretinal fluid at the centre of
macula; prior vitreoretinal surgery; any other intraocular surgerywithin the last 6months;
ongoing neovascular glaucoma; recent anti-VEGF treatment (in the last 6 months);
severe cataract that could affect vision and precise laser treatment; vitreous haemorrhage
severe enough to preclude peripheral retinal laser therapy; tractional retinal detachment;
not enough dilatable pupil
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Pretreatment: there was more high-risk PDR in the intervention group (109 eyes, 81%)
than the comparator (94 eyes, 70%)
Eyes: 285 eyes of 249 people
Interventions Intervention characteristics
Extended targeted retinal photocoagulation
• Type of laser: mixture (532 green laser, diode laser)
• Total number of burns: 1139 to 1318 (mean 1202, SD 33)
• Number of laser sessions: 4
• Laser application (single/multispot): single
• Laser route (slit lamp/fundus camera): slit lamp
• Laser target location (panretinal/ischaemia targeted): ischaemia targeted
• Any additional therapy (non-PDR related): no
• Spot size (µm): 200
• Laser burn intensity (light/moderate/heavy): grade II DRS definition to make
white to light grey burns.
• Laser burn spacing: 0.5 burn
• Any additional information on intervention/comparator: The entire retina
anterior to the equator as well as the capillary non-perfusion areas between the vascular
arcade and the equator were treated. One of the authors specified the capillary non-
perfusion areas on the angiograms.
Conventional PRP
• Type of laser: mixture (532 green laser, diode laser)
• Total number of burns: 1200 to 1600 (mean 1360, SD 108)
• Number of laser sessions: 4
• Laser application (single/multispot): single
• Laser route (slit lamp/fundus camera): slit lamp
• Laser target location (panretinal/ischaemia targeted): PRP
• Any additional therapy (non-PDR related): no
• Spot size (µm): 200
• Laser burn intensity (light/moderate/heavy): grade II DRS definition to make
white to light grey burns
• Laser burn spacing: 0.5 burn
• Any additional information on intervention/comparator: Treatment started from
the vascular arcade toward the periphery.
Outcomes Best corrected visual acuity (measured using Snellen chart and converted to logMAR
for analysis); PDR regression; macular thickness; tractional retinal detachment; ocular
or non-ocular adverse events
Follow-up: 3 months
Notes Funding: NR
Declaration of interest: “The authors declare that they have no financial interest in the
subject matter or materials discussed in this manuscript.”
Country: Iran
Setting: eye Hospital
Date study conducted: October 2011 to December 2014
Trial registration number: NCT01232179
Contacting study investigators: not contacted
61Different lasers and techniques for proliferative diabetic retinopathy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Nikkhah 2017 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The permutated-block random-
ization with varying length of 4, 6, 8 and
10 was selected as the method of random-
ization. Random allocation sequencing was
performed by a biostatistician thorough a
computer generated randomization list.”
Allocation concealment (selection bias) Low risk Quote: “Details of the series were unknown
to the investigators.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: no information on
masking. We assume that in absence of re-
porting on this, participants and personnel
were not masked
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “One senior faculty member vitre-
oretinal specialist other than the authors,
judged PDR regression.”
Judgement comment: It was not clear if this
person was masked or not. We assume that
in absence of reporting on this, outcome
assessors were not masked
Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement comment: follow-up was high
at approximately 95% and was equal fol-
low-up in both groups. There was no ob-
vious reason why loss to follow-up should
be related to outcome
Selective reporting (reporting bias) Unclear risk Judgement comment: there were some
changes from the trial registry entry and
publication. Primary outcome on trial reg-
istry was “no leakage in widefield fluorescin
angiography” at 3months.Other outcomes
were not specified. The primary outcome
in the paper was as follows: “The primary
outcome measure was early PDR regres-
sion, defined as reduction in neovascular
process based on WFFA at three months
after conclusion of laser therapy compared
with baseline”
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Pahor 1998
Methods Study design: randomised controlled trial
Study grouping: parallel group
Participants Baseline Characteristics
Mild scatter PRP
• Number of people (eyes) randomised: NR (NR)
• Number (%) of people followed up: 19 eyes (100%)
• Average age in years: NR
• Age range in years: NR
• Percentage women: NR
• Ethnic group: NR
• Percentage type I diabetes: NR
• Percentage type II diabetes: NR
• BMean baseline visual acuity (SD): 0.95 (0.10) Snellen decimal acuity
Full scatter PRP
• Number of people (eyes) randomised: NR (NR)
• Number (%) of people followed up: 21 eyes (100%)
• Average age in years: NR
• Age range in years: NR
• Percentage women: NR
• Ethnic group: NR
• Percentage type I diabetes: NR
• Percentage type II diabetes: NR
• Mean baseline visual acuity (SD): 0.85 (0.14) Snellen decimal acuity
Overall
• Number of people (eyes) randomised: 47 (62 eyes)
• Number (%) of people followed up: 32 (40 eyes)
• Average age in years: 58
• Age range in years: 38 to 76
• Percentage women: 43%
• Ethnic group: NR
• Percentage type I diabetes: NR
• Percentage type II diabetes: NR
• Mean baseline visual acuity (SD): 0.89 (1.3) Snellen decimal acuity
Inclusion criteria: proliferative or pre-proliferative DR
Exclusion criteria: diseases known to affect visual field as aphakia, cataract, glaucoma,
optic nerve and macular diseases; previous photocoagulation
Pretreatment: Similar visual acuity. Data on other characteristics not reported. “The
mean age and diabetes duration were similar in the two groups.” Eyes: 40 eyes of 32
participants. “The patient’s eyes were randomly assigned to... ”
Eyes: 62 eyes of 47 people
Interventions Intervention characteristics
Mild scatter PRP
• Type of laser: argon
• Total number of burns: 400 to 600 (mean 617, SD 46)
• Number of laser sessions: one
• Laser application (single/multispot): single most likely but not stated
• Laser route (slit lamp/fundus camera): slit lamp most likely but not stated
• Laser target location (panretinal/ischaemia targeted): PRP
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• Any additional therapy (non-PDR related): no
• Spot size (µm):
• Laser burn intensity (light/moderate/heavy): “greyish white coagulation spot was
performed” - moderate
• Laser burn spacing: NR
• Any additional information on intervention/comparator: “Treatment was
administered in topical anesthesia. Themacular region was not treated. All four
quadrants were coagulated, sparing the area between the vascular arcades.”
Full scatter PRP
• Type of laser: argon
• Total number of burns: 1200 to 1600 (mean 1505, SD 450)
• Number of laser sessions: 2 sessions, 2 weeks apart
• Laser application (single/multispot): single most likely but not stated
• Laser route (slit lamp/fundus camera): slit lamp examination most likely but not
stated
• Laser target location (panretinal/ischaemia targeted): PRP
• Any additional therapy (non-PDR related): no
• Spot size (µm): 500
• Laser burn intensity (light/moderate/heavy): “ greyish white coagulation spot was
performed” - moderate
• Laser burn spacing: NR
• Any additional information on intervention/comparator: “Treatment was
administered in topical anesthesia. Themacular region was not treated. All four
quadrants were coagulated, sparing the area between the vascular arcades.”
Outcomes Visual field, retinal sensitivity,
Follow-up: 1 month
Notes Funding: NR
Declaration of interest: NR
Country: Slovenia
Setting: eye Clinic
Date study conducted: NR
Trial registration number: NR
Contacting study investigators: not contacted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The patient’s eyes were randomly
assigned to either full- or mild-scatter pan-
retinal laser coagulation.”
Judgement comment: method of generat-
ing the random allocation sequence not re-
ported
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Allocation concealment (selection bias) Unclear risk Judgement comment: nNot reported how
allocation administered. Trial was de-
scribed as “randomised” but with no fur-
ther details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: no information on
masking. We assume that in absence of re-
porting on this participants and personnel
were not masked
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement comment: no information on
masking. We assume that in absence of re-
porting on this outcome assessors were not
masked
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “22 eyes of 15 patients were ex-
cluded from the study for following rea-
sons: 7 patients (10 eyes) were unable to
perform the automated perimetry reliabil-
ity 1 month after treatment, 5 patients (9
eyes) came not to visual field examination
after 1 month, in 3 patients (3 eyes) the
macular region was treated.” Judgement
comment: total loss to follow-up 38% and
unclear to which group these people were
allocated
Selective reporting (reporting bias) Unclear risk Judgement comment: no access to protocol
or trials registry entry
Tewari 2000
Methods Study design: randomised controlled trial
Study grouping: within-person study
Participants Baseline characteristics
Diode laser
• Number of people (eyes) randomised: 25 (25)
• Number (%) of people followed up: 25 (100%)
• Average age in years: 56
• Age range in years: NR
• Percentage women: NR
• Ethnic group: NR
• Percentage type I diabetes: 0%
• Percentage type II diabetes: 100%
• Mean baseline visual acuity (SD): 3.22 (2.05) reciprocal of Snellen acuity
Argon-green laser
• Number of people (eyes) randomised:25 (25)
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• Number (%) of people followed up: 25 (100%)
• Average age in years: 56
• Age range in years: NR
• Percentage women: NR
• Ethnic group: NR
• Percentage type I diabetes: 0%
• Percentage type II diabetes: 100%
• Mean baseline visual acuity (SD): 4.16 (2.77) reciprocal of Snellen acuity
Overall
• Number of people (eyes) randomised: 25 (50)
• Number (%) of people followed up: 25 (100%)
• Average age in years: 56
• Age range in years: NR
• Percentage women: NR
• Ethnic group: NR
• Percentage type I diabetes: 0%
• Percentage type II diabetes: 100%
• Mean baseline visual acuity (SD): NR
Inclusion criteria: bilateral PDR
Exclusion criteria: “We excluded patients who had previously received photocoagula-
tion; who had hypertensive retinopathy, vascular block, or hazy media; and those in
whom laser delivery was difficult”
Pretreatment: Some difference in average visual acuity but difficult to assess how im-
portant that was
Eyes: within-person study, eye to receive diode laser was randomly allocated, other eye
received argon laser. Analysis was reported separately by eye i.e. was not matched appro-
priately
Interventions Intervention characteristics
Diode laser
• Type of laser: diode laser scatter (810nm)
• Total number of burns: 1439 (SD 206)
• Number of laser sessions: 2 to 4
• Laser application (single/multispot): single
• Laser route (slit lamp/fundus camera): slit lamp
• Laser target location (panretinal/ischaemia targeted): panretinal
• Any additional therapy (non-PDR related):
• Mean laser power and size: 200-500 microns, moderate burn intensity
Argon-green laser
• Type of laser: argon laser scatter (514nm)
• Total number of burns: 1694 (SD 234)
• Number of laser sessions: 2 to 4
• Laser application (single/multispot): single
• Laser route (slit lamp/fundus camera): slit lamp
• Laser target location (panretinal/ischaemia targeted): panretinal
• Any additional therapy (non-PDR related):
• Mean laser power and size: 200-500 microns, moderate burn intensity
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Outcomes Best-corrected visual acuity, peripheral visual field, contrast sensitivity, pain
Follow-up: 6 weeks, 6 months
Notes Funding: NR
Declaration: NR
Country: India
Setting: eye hospital
Date of study: NR
Contacting of study investigator: not contacted
Trial registration number: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote “For each patient, the eye to receive
diode laser was determined randomly with
a coin toss,”
Allocation concealment (selection bias) Unclear risk Quote “For each patient, the eye to receive
diode laser was determined randomly with
a coin toss, and the other eye received argon
laser treatment”
Judgement Comment. In theory this
means that the allocation was unconcealed
but as participants received both treatments
it is unclear if this will have been an issue
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: no information on
masking. We assume that in absence of re-
porting on this participants and personnel
were not masked
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement comment: no information on
masking. We assume that in absence of re-
porting on this outcome assessors were not
masked
Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement Comment: all participants ap-
parently followed up and follow-up identi-
cal between groups because it is a within-
person study
Selective reporting (reporting bias) Unclear risk Judgement comment: no access to protocol
or trials registry entry
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Theodossiadis 1990
Methods Study design: randomised controlled trial
Study grouping: parallel group
Participants Baseline characteristics
Intervention
• Number of people (eyes) randomised: NR (27 eyes)
• Number (%) of people followed up: 100%
• Average age in years: NR
• Age range in years: NR
• Percentage women: NR
• Ethnic group: NR
• Percentage type I diabetes: NR
• Percentage type II diabetes: NR
• Baseline visual acuity (mean, SD): NR
Comparator
• Number of people (eyes) randomised: NR (26 eyes)
• Number (%) of people followed up: 100%
• Average age in years: NR
• Age range in years: NR
• Percentage women: NR
• Ethnic group: NR
• Percentage type I diabetes: NR
• Percentage type II diabetes: NR
• Baseline visual acuity (mean, SD): NR
Overall
• Number of people (eyes) randomised: 42 (53 eyes)
• Number (%) of people followed up: 100%
• Average age in years: NR
• Age range in years: 19-65
• Percentage women: NR
• Ethnic group: NR
• Percentage type I diabetes: NR
• Percentage type II diabetes: NR
• Baseline visual acuity (mean, SD): NR
Inclusion criteria: proliferative retinopathy with 3 or 4 risk factors; clear media; visual
acuity of 0.5 and more; as little macular thickening as possible; had not been treated
with focal laser treatment to the macula
Exclusion criteria: poor cooperation in visual field testing; development of vitreous
haemorrhage; neovascular glaucoma; myocardiopathy
Pretreatment: baseline characteristics not reported.
Eyes: 53 eyes of 42 people.
Interventions Intervention characteristics
Intervention
• Type of laser: blue-green argon laser
• Total number of burns: 1500 to 3000
• Number of laser sessions: 3
• Laser application (single/multispot): single
• Laser route (slit lamp/fundus camera): slit lamp
• Laser target location (panretinal/ischaemia targeted): pan but reduced area:
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stopped 1 DD from the optic disc nasal margin and 3 DD from the upper, lower and
temporal margins of the fovea
• Any additional therapy (non-PDR related): no
• Spot size (µm): 200 to 500
• Laser burn intensity (light/moderate/heavy): moderate blanching
• Laser burn spacing: “more closely spaced”
• Any additional information on intervention/comparator: none
Comparator
• Type of laser: blue-green argon laser
• Total number of burns: 1500 to 3000
• Number of laser sessions: 3
• Laser application (single/multispot): single
• Laser route (slit lamp/fundus camera): slit lamp
• Laser target location (panretinal/ischaemia targeted): pan, covered the entire
peripheral retina and mid-periphery, sparing an area of 2 DD from the fovea
• Any additional therapy (non-PDR related): no
• Spot size (µm): 200 to 500
• Laser burn intensity (light/moderate/heavy): moderate blanching
• Laser burn spacing: chessboard pattern
• Any additional information on intervention/comparator: none
Outcomes Visual fields; retinal sensitivity; visual acuity; regression of neovascularisation
Follow-up: 2 years
Notes Funding: NR
Declaration: NR
Country: Greece
Setting: Eye Hospital
Date study conducted: NR
Trial registration number: NR
Contacting study investigators: not contacted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: randomly assigned
but no detail given
Allocation concealment (selection bias) Unclear risk Judgement comment: NR not recorded so
assume not done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: NR not recorded so
assumed not masked
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement comment: not recorded so as-
sume not done
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: unclear if excluded
participants had been randomised or not
before exclusion
Selective reporting (reporting bias) Unclear risk Judgement comment: no protocol available
Wade 1990
Methods Study design: randomised controlled trial
Study grouping: parallel group
Participants Baseline Characteristics
Intervention (argon long exposure (0.5 s))
• Number of people (eyes) randomised: 24 (25 eyes)
• Number (%) of people followed up: 24 eyes (96%)
• Average age in years: 49
• Age range in years: 19 to 71
• Percentage women: 50%
• Ethnic group: NR
• Percentage type I diabetes: NR
• Percentage type II diabetes: NR
• Baseline visual acuity (mean, SD): NR
Comparator (argon standard exposure (0.1 s)
• Number of people (eyes) randomised: 19 (25 eyes)
• Number (%) of people followed up: 20 eyes (80%)
• Average age in years: 48
• Age range in years: 18 to 82
• Percentage women: 52%
• Ethnic group: NR
• Percentage type I diabetes: NR
• Percentage type II diabetes: NR
• Baseline visual acuity (mean, SD): NR
Overall
• Number of people (eyes) randomised: 41 (50 eyes)
• Number (%) of people followed up: 43 eyes
• Average age in years: 49
• Age range in years: 18 to 82
• Percentage women: 51%
• Ethnic group: NR
• Percentage type I diabetes: NR
• Percentage type II diabetes: NR
• Baseline visual acuity (mean, SD): NR
Included criteria: the participant had to have a diagnosis of diabetes mellitus, be able
to return for post-laser examinations at 1 week, 1 month, and 6 months, and be willing
to participate in a random selection of either 0.l-s or 0.5-s burn exposure time. Ocular
eligibility criteria of the involved eye required best corrected visual acuity of 6/30 or
better, media clarity sufficient for PRP in a single session and three or four diabetic
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retinopathy risk factors
Excluded criteria: eyes with prior photocoagulation, or substantial lens or vitreous
opacities sufficient to prevent PRP, were ineligible
Pretreatment: some imbalance in visual acuity but with small numbers probably by
chance. Similar numbers of men and women and average age
Eyes: 50 eyes of 41 people
Interventions Intervention characteristics
Intervention
• Type of laser: 0.5 second exposure time with argon laser
• Total number of burns: between 500 to 900 (mean 710)
• Number of laser sessions: 1
• Laser application (single/multispot): single
• Laser route (slit lamp/fundus camera): slit lamp
• Laser target location (panretinal/ischaemia targeted): PRP standard
• Any additional therapy (non-PDR related): none
• Spot size (µm): 500
• Laser burn intensity (light/moderate/heavy): moderate
• Laser burn spacing: one half burn width apart
• Any additional information on intervention/comparator: Retrobulbar anaesthesia
in all cases
Comparator
• Type of laser: 0.1 laser exposure time with argon laser
• Total number of burns: between 650 to 1000 (mean 767)
• Number of laser sessions: 1
• Laser application (single/multispot): single
• Laser route (slit lamp/fundus camera): slit lamp
• Laser target location (panretinal/ischaemia targeted): PRP standard
• Any additional therapy (non-PDR related): none
• Spot size (µm): 500
• Laser burn intensity (light/moderate/heavy): moderate
• Laser burn spacing: one half burn width apart
• Any additional information on intervention/comparator: Retrobulbar anaesthesia
in all cases
Outcomes Visual acuity (Snellen); changes in neovascularisation of the disc and retina; macular
thickening; choroidal and retinal detachments; vitreous haemorrhages
Follow-up: 6 months
Notes Funding: this project was supported in part by the Bascorn Palmer Eye Institute, De-
partment of Ophthalmology,University ofMiami, and the participants and contributors
of the Department of Ophthalmology at Penn State College of Medicine; Research to
Prevent Blindness. Inc., New York City; Florida Lions Eye Bank Laboratory and the
Benn Green Diabetic Retinopathy Fund, Miami, Florida
Declaration: NR
Country: USA
Setting: eye Hospital
Date study conducted: NR
Trial registration number: NR
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Contacting study investigators: not contacted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Judgement comment: allocation was by
coin toss
Allocation concealment (selection bias) Unclear risk Not reported how allocation administered.
Trial was described “randomised” but with
no further details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: no information on
masking. We assume that in absence of re-
porting on this, participants and personnel
were not masked
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgment comment: no information on
masking. We assume that in absence of re-
porting on this, outcome assessors were not
masked
Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement comment: loss to follow-up was
low (< 20%) and equal
Selective reporting (reporting bias) Unclear risk No access to trial protocol or registry entry
SD: standard deviation
NR: not reported
PDR: proliferative diabetic retinopathy
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Al Hussainy 2008 No standard comparator group - Nd:YAG laser only
Alvarez Verduzco 2010 Not a randomised controlled trial
Beetham 1969 Ruby laser no longer in common use
Belucio-Neto 2015 No standard (argon laser) comparator group
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Blankenship 1986 Krypton laser not in common use
Blankenship 1991 No standard comparator group - argon laser compared with xenon laser and untreated comparator group
Canning 1991 Relevant outcomes not reported and may not have been measured as study focuses on macular function.
Study too old (<25 years) to obtain data from investigators
Capoferri 1990 Krypton laser not in common use
Chen 2004 Krypton laser not in common use
Chen 2013 No standard (argon laser) comparator group
Chew 1991 Krypton laser no longer in common use
Chhablani 2014 No standard (argon laser) comparator group
Crick 1978 Xenon laser no longer in common use
Doft 1982 Compared single versus multiple treatment sessions which was not one of our pre-defined comparisons
Dong 2008 Not a randomised controlled trial
Fankhauser 1972 Not a randomised controlled trial
Francois 1971 Xenon laser no longer in common use
Francois 1977 Not a randomised controlled trial
Geltzer 1972 Not a randomised controlled trial
Ghassemi 2013 Measured nerve fibre layer thickness only
Guo 2013 Compared one versus two sittings which was not one of our pre-defined comparisons
Hamilton 1981 Xenon laser no longer in common use
Inan 2016 No standard comparator group
KARNS 1994 Krypton laser no longer in common use
Khosla 1994 Compared one versus two sittings which was not one of our pre-defined comparisons
Kovacic 2012 Not a randomised controlled trial
Li 1986 Only measured electroretinographic changes
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Liang 1983 Xenon arc laser not in use any more
Lopez 2008 Not a randomised controlled trial
Ludwig 1994 Not a randomised controlled trial
MAPASS 2010 No standard (argon) comparator group - pascal laser only (532nm)
McLean 1976 Xenon laser no longer in common use
Menchini 1990 Krypton laser no longer in common use
Menchini 1995 Krypton laser no longer in common use
Mirshahi 2013 No standard (argon) comparator group - Nd:YAG (532nm) laser only
Muraly 2011 No standard (argon) comparator group - Nd:YAG (532nm) laser only
Nagpal 2008 No standard (argon) comparator group (conference abstract only)
Nagpal 2010 No standard (argon) comparator group (conference abstract only)
Peng 2013 No standard (argon) comparator group
PETER PAN 2011 No standard (argon) comparator group - PASCAL laser only
Plumb 1982 Xenon arc laser no longer in common use.
Roohipoor 2016 Intervention not in common use (red laser)
Sato 2012 Participants had pre-proliferative diabetic retinopathy
Schulenburg 1979 Krypton laser not in common use
Seiberth 1987 Participants in this study had pre-proliferative diabetic retinopathy
Seiberth 1993 Participants had pre-proliferative diabetic retinopathy
Seymenoglu 2013 Not a randomised controlled trial
Shiraya 2014 Not a randomised controlled trial
Ulbig 1994 Not a randomised controlled trial
Yassur 1980 No standard (argon) comparator group - comparator group was untreated
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Yilmaz 2016 Not a randomised controlled trial
Zhang 2017 No standard (argon) comparator group - pattern scan (577nm) only
Characteristics of studies awaiting assessment [ordered by study ID]
Chaine 1986
Methods Prospective study
Participants People with proliferative diabetic retinopathy
Interventions Panretinal photocoagulation
Outcomes Not known
Notes We were unable to find either an abstract or a full text copy of this citation
Kianersi 2016
Methods Within-person study
Participants 146 eyes of 73 participants with proliferative diabetic retinopathy
Interventions • Single spot laser photocoagulation
• Pattern scan laser photocoagulation
Unclear what laser was used
Outcomes • Changes in retinal ischemia
• Regression of neovascularisation
Follow-up: 6 months
Quote “Findings: There was no significant difference in the retinal neovascularization regression of disc and elsewhere
in eyes treated with pattern scan (P = 0.26) or single spot laser (P = 0.31). While the areas of the retinal ischemia
progression was significantly higher (9 cases) in group treated with pattern scan in comparison to other group (2
cases) (P = 0.02).”
Notes We were unable to source a copy of this and did not receive a response from the author
Salman 2011
Methods Parallel group study
Participants 60 people with PDR
Interventions Pascal versus conventional laser
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Outcomes Successful outcome
Notes Investigator contacted but no reply.
Uehara 1993
Methods Within-person study
Participants People with bilateral early stage proliferative diabetic retinopathy (n=17)
Interventions “Slight” photocoagulation (laser burns were 405 +/- 166)
“Heavy” photocoagulation (laser burns were 1142 +/- 179)
Outcomes • Assessment of fundus pictures
• Visual acuity
• Posterior vitreous fluorophotometric values
Follow-up: more than 6 months after the last photocoagulation
Quote “The results of judgement by fundus pictures and by vitreous fluorophotometric values were in perfect
agreement. Eight cases (47%) in whom eyes received slight photocoagulation showed result better than the other eye.
Two cases (12%) which received heavy photocoagulation were better than the other eye. Seven cases (41%) showed
the same level of severity. No significant differences were found between slight and heavy photocoagulation.”
Notes Awaiting translation
Wroblewski 1991
Methods Prospective study, possibly randomised
Participants Quote “30 eyes with PDR and presenting visual acuity of 20/100 or better. Eyes with vitreous hemorrhage or prior
laser treatment were excluded.”
Interventions Central PRP (n=16 eyes) versus peripheral PRP (n=14 eyes)
Quote “A Mainster panfunduscopic lens was used to deliver 1600 spots in 500 micron size in each group.”
Outcomes Macular oedema, visual acuity, retinal detachment, decrease in vision
Follow-up: 6 weeks and 5 months
Notes Quote “There was no significant difference in either group in. macular edema on IVFA. Three eyes (20%) have lost
two lines of Snellen acuity at their six week follow up in the central group, but no significant difference in the final
visual accuity was noted at the five month follow up. One eye in the central group and two in the peripheral group
also developed fractional macular retinal detachment. Central PRP in PDR may carry a higher incidence of transient
decrease in vision compared to peripheral PRP. An analysis of the risk factors in these 30 eyes is presented.”
Reported as abstract only.We contacted author for further clarification as to whether this was a randomised controlled
trial but did not receive any reply
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Methods Randomised controlled trial
Participants People with diabetic retinopathy
Interventions • Patterned panretinal photocoagulation with short laser exposure time (0.02 seconds)
• Conventional panretinal photocoagulation with long laser exposure time (0.2 seconds)
Outcomes • Progression of diabetic retinopathy
• Best-corrected visual acuity
• Central macular thickness
• Pain during treatment
Follow-up: 1, 2, 4, 8 weeks and 1 year
Quote “The progression of diabetic retinopathy was not different in both groups at the 1-year follow-up visit. The
best-corrected visual acuities at 1, 2, 4, and 8 weeks after PRP were decreased in both groups and, in the conventional
PRP group, the decrements of visual acuity were greater than in the patterned PRP group. The increments of central
macular thickness were also greater in the conventional PRP group than the patterned PRP group.”
Notes Awaiting translation
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D A T A A N D A N A L Y S E S
Comparison 1. Nd:YAG laser vs argon laser
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 BCVA: loss of 15 or more
ETDRS letters
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 BCVA: gain of 15 or more
ETDRS letters
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
3 Change in BCVA Other data No numeric data
4 Progression of PDR 1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
5 Regression of PDR 1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
6 Pain during laser treatment 2 62 Risk Ratio (IV, Fixed, 95% CI) 1.0 [0.36, 2.76]
7 Adverse effects 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Vitreous haemorrhage 2 62 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.38, 3.94]
7.2 Choroidal detachment 2 62 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.04, 1.27]
7.3 Troublesome pain 1 20 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.17, 5.77]
7.4 Neurotrophic keratopathy 2 62 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.35, 4.75]
Comparison 2. Diode versus argon laser
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 BCVA: loss of 15 or more
ETDRS letters
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 BCVA: gain of 15 or more
ETDRS letters
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
3 Change in BCVA Other data No numeric data
4 Progression of PDR 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Regression of PDR 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Pain during laser treatment 3 202 Risk Ratio (M-H, Fixed, 95% CI) 3.12 [2.16, 4.51]
7 Adverse effects 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Vitreous haemorrhage 2 152 Risk Ratio (M-H, Fixed, 95% CI) 1.80 [0.91, 3.53]
7.2 Choroidal detachment 1 44 Risk Ratio (M-H, Fixed, 95% CI) 4.0 [0.48, 33.00]
7.3 Neurotrophic keratopathy 1 44 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 69.87]
7.4 Maculopathy 1 108 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.54, 3.13]
7.5 Cataract 1 108 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.17, 1.57]
7.6 Pre-retinal membrane 1 108 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.24, 5.49]
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Comparison 3. 0.5 versus 0.1 second exposure
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 BCVA: loss of 15 or more
EDTRS letters
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 BCVA: gain of 15 or more
EDTRS letters
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Progression of PDR 1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
4 Regression of PDR 1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
5 Adverse effects 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Pre-retinal or vitreous
haemorrhage
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Macular thickening 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Combined rhegmatous
and traction retinal detachment
requiring pars plana vitrectomy
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. Light versus classic
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in BCVA 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Pain during laser treatment 1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
3 Adverse effects 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Vitreous haemorrhage 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Choroidal detachment 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Neurotrophic keratopathy 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Clinically significant
macular oedema
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 5. Mild scatter PRP vs full scatter PRP
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in BCVA Other data No numeric data
2 Visual field (mean deviation) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Comparison 6. Central versus peripheral
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 BCVA: loss of 15 or more
ETDRS letters
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 BCVA: gain of 15 or more
ETDRS letters
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
3 Needing further laser treatment
after initial treatment period
i.e. after 3 months.
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
4 Adverse effects 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Vitreous haemorrhage 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Macular traction
detachment
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Macular thickening 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 7. Centre sparing versus full scatter PRP
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 BCVA: loss of 15 or more
ETDRS letters
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Regression of PDR 1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Comparison 8. Extended targeted PRP versus standard PRP
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 BCVA: loss of 15 or more letters 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Change in BCVA 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Regression of PDR 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Change in central macular
thickness
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Nd:YAG laser vs argon laser, Outcome 1 BCVA: loss of 15 or more ETDRS
letters.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 1 Nd:YAG laser vs argon laser
Outcome: 1 BCVA: loss of 15 or more ETDRS letters
Study or subgroup Nd:YAG laser Argon laser Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Brancato 1991 (1) 4/10 5/10 0.80 [ 0.30, 2.13 ]
0.1 0.2 0.5 1 2 5 10
Favours Nd:YAG Favours argon
(1) 6 months, 2 or more lines Snellen acuity
Analysis 1.2. Comparison 1 Nd:YAG laser vs argon laser, Outcome 2 BCVA: gain of 15 or more ETDRS
letters.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 1 Nd:YAG laser vs argon laser
Outcome: 2 BCVA: gain of 15 or more ETDRS letters
Study or subgroup Nd:YAG laser Argon laser Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Brancato 1991 (1) 0/10 1/10 0.33 [ 0.02, 7.32 ]
0.1 0.2 0.5 1 2 5 10
Favours argon Favours Nd:YAG
(1) 6 months, 2 or more lines Snellen acuity
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Analysis 1.3. Comparison 1 Nd:YAG laser vs argon laser, Outcome 3 Change in BCVA.
Change in BCVA
Study Nd: YAG: mean decimal
Snellen acuity at follow-
up (SD)
N Argon: mean decimal Snellen acuity
at follow-up (SD)
N
Bandello 1996 0.5 (0.25) 21 0.45 (0.27) 21
Brancato 1991 0.5 (0.25) 10 0.5 (0.25) 10
Analysis 1.4. Comparison 1 Nd:YAG laser vs argon laser, Outcome 4 Progression of PDR.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 1 Nd:YAG laser vs argon laser
Outcome: 4 Progression of PDR
Study or subgroup Nd:YAG laser Argon laser Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Bandello 1996 (1) 1/21 1/21 1.00 [ 0.07, 14.95 ]
0.1 0.2 0.5 1 2 5 10
Favours Nd:YAG Favours argon
(1) 29 months, PDR ”worsened”
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Analysis 1.5. Comparison 1 Nd:YAG laser vs argon laser, Outcome 5 Regression of PDR.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 1 Nd:YAG laser vs argon laser
Outcome: 5 Regression of PDR
Study or subgroup Nd:YAG laser Argon laser Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Bandello 1996 (1) 20/21 20/21 1.00 [ 0.87, 1.14 ]
0.1 0.2 0.5 1 2 5 10
Favours argon Favours Nd:YAG
(1) 29 months, PDR ”improved”
Analysis 1.6. Comparison 1 Nd:YAG laser vs argon laser, Outcome 6 Pain during laser treatment.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 1 Nd:YAG laser vs argon laser
Outcome: 6 Pain during laser treatment
Study or subgroup Nd:YAG laser Argon laser Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Bandello 1996 (1) 4/21 4/21 66.4 % 1.00 [ 0.29, 3.48 ]
Brancato 1991 2/10 2/10 33.6 % 1.00 [ 0.17, 5.77 ]
Total (95% CI) 31 31 100.0 % 1.00 [ 0.36, 2.76 ]
Total events: 6 (Nd:YAG laser), 6 (Argon laser)
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Nd:YAG Favours argon
(1) ”troublesome” pain during and immediately after laser treatment
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Analysis 1.7. Comparison 1 Nd:YAG laser vs argon laser, Outcome 7 Adverse effects.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 1 Nd:YAG laser vs argon laser
Outcome: 7 Adverse effects
Study or subgroup Nd:YAG laser Argon laser Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitreous haemorrhage
Bandello 1996 5/21 2/21 44.4 % 2.50 [ 0.54, 11.48 ]
Brancato 1991 0/10 2/10 55.6 % 0.20 [ 0.01, 3.70 ]
Subtotal (95% CI) 31 31 100.0 % 1.22 [ 0.38, 3.94 ]
Total events: 5 (Nd:YAG laser), 4 (Argon laser)
Heterogeneity: Chi2 = 2.32, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 0.34 (P = 0.74)
2 Choroidal detachment
Bandello 1996 1/21 5/21 76.9 % 0.20 [ 0.03, 1.57 ]
Brancato 1991 0/10 1/10 23.1 % 0.33 [ 0.02, 7.32 ]
Subtotal (95% CI) 31 31 100.0 % 0.23 [ 0.04, 1.27 ]
Total events: 1 (Nd:YAG laser), 6 (Argon laser)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.092)
3 Troublesome pain
Brancato 1991 2/10 2/10 100.0 % 1.00 [ 0.17, 5.77 ]
Subtotal (95% CI) 10 10 100.0 % 1.00 [ 0.17, 5.77 ]
Total events: 2 (Nd:YAG laser), 2 (Argon laser)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 Neurotrophic keratopathy
Bandello 1996 3/21 3/21 85.7 % 1.00 [ 0.23, 4.40 ]
Brancato 1991 1/10 0/10 14.3 % 3.00 [ 0.14, 65.90 ]
Subtotal (95% CI) 31 31 100.0 % 1.29 [ 0.35, 4.75 ]
Total events: 4 (Nd:YAG laser), 3 (Argon laser)
Heterogeneity: Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.71)
Test for subgroup differences: Chi2 = 3.01, df = 3 (P = 0.39), I2 =0%
0.01 0.1 1 10 100
Favours Nd:YAG Favours argon
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Analysis 2.1. Comparison 2 Diode versus argon laser, Outcome 1 BCVA: loss of 15 or more ETDRS letters.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 2 Diode versus argon laser
Outcome: 1 BCVA: loss of 15 or more ETDRS letters
Study or subgroup Diode Argon Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Han 1995 (1) 19/50 20/58 1.10 [ 0.67, 1.82 ]
0.1 0.2 0.5 1 2 5 10
Favours diode Favours argon
(1) 1 year, ”worsened” visual acuity
Analysis 2.2. Comparison 2 Diode versus argon laser, Outcome 2 BCVA: gain of 15 or more ETDRS letters.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 2 Diode versus argon laser
Outcome: 2 BCVA: gain of 15 or more ETDRS letters
Study or subgroup Diode Argon Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Han 1995 (1) 6/50 11/58 0.63 [ 0.25, 1.59 ]
0.1 0.2 0.5 1 2 5 10
Favours argon Favours diode
(1) 1 year, ”improved” visual acuity
Analysis 2.3. Comparison 2 Diode versus argon laser, Outcome 3 Change in BCVA.
Change in BCVA
Study Follow-up Diode:
mean Snellen dec-
imal acuity at fol-
low-up (SD)
N Argon: mean Snellen deci-
mal acuity at follow-up (SD)
N
Bandello 1993 Average of approxi-
mately 2 years (24
months)
0.4 (0.3) 22 0.4 (0.3) 22
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Change in BCVA (Continued)
Tewari 2000 6 months 3,62 (2.12) recipro-
cal of Snellen decimal
acuity
25 4.76 (2.83) reciprocal of
Snellen decimal acuity
25
Analysis 2.4. Comparison 2 Diode versus argon laser, Outcome 4 Progression of PDR.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 2 Diode versus argon laser
Outcome: 4 Progression of PDR
Study or subgroup Diode Argon Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Han 1995 (1) 8/31 10/35 0.90 [ 0.41, 2.00 ]
0.1 0.2 0.5 1 2 5 10
Favours diode Favours argon
(1) 1 year, PDR ”worsened”
Analysis 2.5. Comparison 2 Diode versus argon laser, Outcome 5 Regression of PDR.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 2 Diode versus argon laser
Outcome: 5 Regression of PDR
Study or subgroup Diode Argon Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Han 1995 (1) 8/31 12/35 0.75 [ 0.35, 1.60 ]
0.1 0.2 0.5 1 2 5 10
Favours argon Favours diode
(1) 1 year, PDR ”improved”
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Analysis 2.6. Comparison 2 Diode versus argon laser, Outcome 6 Pain during laser treatment.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 2 Diode versus argon laser
Outcome: 6 Pain during laser treatment
Study or subgroup Diode Argon Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bandello 1993 8/22 4/22 17.4 % 2.00 [ 0.70, 5.68 ]
Han 1995 38/50 13/58 52.3 % 3.39 [ 2.05, 5.61 ]
Tewari 2000 23/25 7/25 30.4 % 3.29 [ 1.73, 6.23 ]
Total (95% CI) 97 105 100.0 % 3.12 [ 2.16, 4.51 ]
Total events: 69 (Diode), 24 (Argon)
Heterogeneity: Chi2 = 0.83, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 6.04 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours diode Favours argon
Analysis 2.7. Comparison 2 Diode versus argon laser, Outcome 7 Adverse effects.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 2 Diode versus argon laser
Outcome: 7 Adverse effects
Study or subgroup Diode Argon Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitreous haemorrhage
Bandello 1993 7/22 4/22 38.2 % 1.75 [ 0.60, 5.14 ]
Han 1995 11/50 7/58 61.8 % 1.82 [ 0.76, 4.35 ]
Subtotal (95% CI) 72 80 100.0 % 1.80 [ 0.91, 3.53 ]
Total events: 18 (Diode), 11 (Argon)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.090)
2 Choroidal detachment
Bandello 1993 4/22 1/22 100.0 % 4.00 [ 0.48, 33.00 ]
0.01 0.1 1 10 100
Favours diode Favours argon
(Continued . . . )
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(. . . Continued)
Study or subgroup Diode Argon Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 22 22 100.0 % 4.00 [ 0.48, 33.00 ]
Total events: 4 (Diode), 1 (Argon)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
3 Neurotrophic keratopathy
Bandello 1993 1/22 0/22 100.0 % 3.00 [ 0.13, 69.87 ]
Subtotal (95% CI) 22 22 100.0 % 3.00 [ 0.13, 69.87 ]
Total events: 1 (Diode), 0 (Argon)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
4 Maculopathy
Han 1995 9/50 8/58 100.0 % 1.31 [ 0.54, 3.13 ]
Subtotal (95% CI) 50 58 100.0 % 1.31 [ 0.54, 3.13 ]
Total events: 9 (Diode), 8 (Argon)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
5 Cataract
Han 1995 4/50 9/58 100.0 % 0.52 [ 0.17, 1.57 ]
Subtotal (95% CI) 50 58 100.0 % 0.52 [ 0.17, 1.57 ]
Total events: 4 (Diode), 9 (Argon)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.24)
6 Pre-retinal membrane
Han 1995 3/50 3/58 100.0 % 1.16 [ 0.24, 5.49 ]
Subtotal (95% CI) 50 58 100.0 % 1.16 [ 0.24, 5.49 ]
Total events: 3 (Diode), 3 (Argon)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Chi2 = 4.85, df = 5 (P = 0.43), I2 =0.0%
0.01 0.1 1 10 100
Favours diode Favours argon
88Different lasers and techniques for proliferative diabetic retinopathy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.1. Comparison 3 0.5 versus 0.1 second exposure, Outcome 1 BCVA: loss of 15 or more EDTRS
letters.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 3 0.5 versus 0.1 second exposure
Outcome: 1 BCVA: loss of 15 or more EDTRS letters
Study or subgroup 0.5 second 0.1 second Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wade 1990 (1) 2/24 4/20 0.42 [ 0.08, 2.04 ]
0.1 0.2 0.5 1 2 5 10
Favours 0.5s Favours 0.1s
(1) 6 months, loss of 2 or more Snellen lines
Analysis 3.2. Comparison 3 0.5 versus 0.1 second exposure, Outcome 2 BCVA: gain of 15 or more EDTRS
letters.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 3 0.5 versus 0.1 second exposure
Outcome: 2 BCVA: gain of 15 or more EDTRS letters
Study or subgroup 0.5 second 0.1 second Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wade 1990 (1) 8/24 3/20 2.22 [ 0.68, 7.28 ]
0.1 0.2 0.5 1 2 5 10
Favours 0.1s Favours 0.5s
(1) 6 months, gain of 2 or more Snellen lines
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Analysis 3.3. Comparison 3 0.5 versus 0.1 second exposure, Outcome 3 Progression of PDR.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 3 0.5 versus 0.1 second exposure
Outcome: 3 Progression of PDR
Study or subgroup 0.5 second 0.1 second Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Wade 1990 (1) 0/8 1/8 0.33 [ 0.02, 7.14 ]
0.1 0.2 0.5 1 2 5 10
Favours 0.5s Favours 0.1s
(1) 6 months, increased neovascularisation of the disc
Analysis 3.4. Comparison 3 0.5 versus 0.1 second exposure, Outcome 4 Regression of PDR.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 3 0.5 versus 0.1 second exposure
Outcome: 4 Regression of PDR
Study or subgroup 0.5 second 0.1 second Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Wade 1990 (1) 18/18 12/14 1.17 [ 0.92, 1.48 ]
0.1 0.2 0.5 1 2 5 10
Favours 0.1s Favours 0.5s
(1) 6 months, less neovascularisation of the disc
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Analysis 3.5. Comparison 3 0.5 versus 0.1 second exposure, Outcome 5 Adverse effects.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 3 0.5 versus 0.1 second exposure
Outcome: 5 Adverse effects
Study or subgroup 0.5 second 0.1 second Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pre-retinal or vitreous haemorrhage
Wade 1990 4/24 6/20 0.56 [ 0.18, 1.70 ]
2 Macular thickening
Wade 1990 0/24 2/20 0.17 [ 0.01, 3.31 ]
3 Combined rhegmatous and traction retinal detachment requiring pars plana vitrectomy
Wade 1990 1/24 0/20 2.52 [ 0.11, 58.67 ]
0.01 0.1 1 10 100
Favours 0.5s Favours 0.1s
Analysis 4.1. Comparison 4 Light versus classic, Outcome 1 Change in BCVA.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 4 Light versus classic
Outcome: 1 Change in BCVA
Study or subgroup Light Classic
Mean
Difference
Mean
Difference
N Mean(SD)[logMAR] N Mean(SD)[logMAR] IV,Fixed,95% CI IV,Fixed,95% CI
Bandello 2001 (1) 34 0.18 (0.25) 31 0.27 (0.3) -0.09 [ -0.22, 0.04 ]
-1 -0.5 0 0.5 1
Favours light Favours classic
(1) 1 year
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Analysis 4.2. Comparison 4 Light versus classic, Outcome 2 Pain during laser treatment.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 4 Light versus classic
Outcome: 2 Pain during laser treatment
Study or subgroup Light Classic Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Bandello 2001 1/34 4/31 0.23 [ 0.03, 1.93 ]
0.1 0.2 0.5 1 2 5 10
Favours light Favours classic
Analysis 4.3. Comparison 4 Light versus classic, Outcome 3 Adverse effects.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 4 Light versus classic
Outcome: 3 Adverse effects
Study or subgroup Light Classic Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitreous haemorrhage
Bandello 2001 0/34 6/31 0.07 [ 0.00, 1.20 ]
2 Choroidal detachment
Bandello 2001 0/34 3/31 0.13 [ 0.01, 2.43 ]
3 Neurotrophic keratopathy
Bandello 2001 0/34 2/31 0.18 [ 0.01, 3.67 ]
4 Clinically significant macular oedema
Bandello 2001 1/34 7/31 0.13 [ 0.02, 1.00 ]
0.01 0.1 1 10 100
Favours light Favours classic
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Analysis 5.1. Comparison 5 Mild scatter PRP vs full scatter PRP, Outcome 1 Change in BCVA.
Change in BCVA
Study Mild scatter:mean Snellen
decimal acuity (SD)
N Full scatter: mean Snellen decimal
acuity (SD)
N
Pahor 1998 0.93 (0.11) 19 0.89 (0.19) 21
Analysis 5.2. Comparison 5 Mild scatter PRP vs full scatter PRP, Outcome 2 Visual field (mean deviation).
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 5 Mild scatter PRP vs full scatter PRP
Outcome: 2 Visual field (mean deviation)
Study or subgroup Mild scatter PRP Full scatter PRP
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Pahor 1998 (1) 19 3.25 (2.19) 21 5.75 (3.29) -2.50 [ -4.22, -0.78 ]
-10 -5 0 5 10
Favours Mild scatter PRP Favours Full scatter PRP
(1) 3 months
Analysis 6.1. Comparison 6 Central versus peripheral, Outcome 1 BCVA: loss of 15 or more ETDRS letters.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 6 Central versus peripheral
Outcome: 1 BCVA: loss of 15 or more ETDRS letters
Study or subgroup Central Peripheral Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Blankenship 1988 (1) 6/25 2/25 3.00 [ 0.67, 13.46 ]
0.1 0.2 0.5 1 2 5 10
Favours central Favours peripheral
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(1) 6 months, 2 or more lines Snellen acuity
Analysis 6.2. Comparison 6 Central versus peripheral, Outcome 2 BCVA: gain of 15 or more ETDRS letters.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 6 Central versus peripheral
Outcome: 2 BCVA: gain of 15 or more ETDRS letters
Study or subgroup Central Peripheral Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Blankenship 1988 (1) 1/25 4/25 0.25 [ 0.03, 2.08 ]
0.1 0.2 0.5 1 2 5 10
Favours peripheral Favours central
(1) 6 months, 2 or more lines Snellen acuity
Analysis 6.3. Comparison 6 Central versus peripheral, Outcome 3 Needing further laser treatment after
initial treatment period i.e. after 3 months..
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 6 Central versus peripheral
Outcome: 3 Needing further laser treatment after initial treatment period i.e. after 3 months.
Study or subgroup Central Peripheral Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Blankenship 1988 1/25 1/25 1.00 [ 0.07, 15.12 ]
0.1 0.2 0.5 1 2 5 10
Favours central Favours peripheral
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Analysis 6.4. Comparison 6 Central versus peripheral, Outcome 4 Adverse effects.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 6 Central versus peripheral
Outcome: 4 Adverse effects
Study or subgroup Central Peripheral Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitreous haemorrhage
Blankenship 1988 1/25 1/25 1.00 [ 0.07, 15.12 ]
2 Macular traction detachment
Blankenship 1988 3/25 1/25 3.00 [ 0.33, 26.92 ]
3 Macular thickening
Blankenship 1988 2/25 2/25 1.00 [ 0.15, 6.55 ]
0.01 0.1 1 10 100
Favours central Favours peripheral
Analysis 7.1. Comparison 7 Centre sparing versus full scatter PRP, Outcome 1 BCVA: loss of 15 or more
ETDRS letters.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 7 Centre sparing versus full scatter PRP
Outcome: 1 BCVA: loss of 15 or more ETDRS letters
Study or subgroup Centre sparing Full scatter Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Theodossiadis 1990 (1) 7/27 10/26 0.67 [ 0.30, 1.50 ]
0.1 0.2 0.5 1 2 5 10
Favours centre sparing Favours full scatter
(1) 53 eyes of 42 patients, 6 months, deteriorated by 0.1-0.2, probably Snellen acuity
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Analysis 7.2. Comparison 7 Centre sparing versus full scatter PRP, Outcome 2 Regression of PDR.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 7 Centre sparing versus full scatter PRP
Outcome: 2 Regression of PDR
Study or subgroup Centre sparing Full scatter Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Theodossiadis 1990 21/27 21/26 0.96 [ 0.73, 1.27 ]
0.1 0.2 0.5 1 2 5 10
Favours full scatter Favours centre sparing
Analysis 8.1. Comparison 8 Extended targeted PRP versus standard PRP, Outcome 1 BCVA: loss of 15 or
more letters.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 8 Extended targeted PRP versus standard PRP
Outcome: 1 BCVA: loss of 15 or more letters
Study or subgroup Extended Standard Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nikkhah 2017 (1) 50/135 53/135 0.94 [ 0.70, 1.28 ]
0.1 0.2 0.5 1 2 5 10
Favours extended Favours standard
(1) ”worsened” visual acuity at 3 months
96Different lasers and techniques for proliferative diabetic retinopathy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.2. Comparison 8 Extended targeted PRP versus standard PRP, Outcome 2 Change in BCVA.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 8 Extended targeted PRP versus standard PRP
Outcome: 2 Change in BCVA
Study or subgroup Extended Standard
Mean
Difference
Mean
Difference
N Mean(SD)[logMAR] N Mean(SD)[logMAR] IV,Fixed,95% CI IV,Fixed,95% CI
Nikkhah 2017 (1) 135 0.47 (0.19) 135 0.47 (0.24) 0.0 [ -0.05, 0.05 ]
-1 -0.5 0 0.5 1
Favours extended Favours standard
(1) final visual acuity at 3 months
Analysis 8.3. Comparison 8 Extended targeted PRP versus standard PRP, Outcome 3 Regression of PDR.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 8 Extended targeted PRP versus standard PRP
Outcome: 3 Regression of PDR
Study or subgroup Extended Standard Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nikkhah 2017 (1) 97/135 87/135 1.11 [ 0.95, 1.31 ]
0.1 0.2 0.5 1 2 5 10
Favours standard Favours extended
(1) 3 months: retinopathy no longer was in the high-risk category (in the previously diagnosed high-risk PDR eyes) or neovascular activity was reduced (in the early PDR
cases)
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Analysis 8.4. Comparison 8 Extended targeted PRP versus standard PRP, Outcome 4 Change in central
macular thickness.
Review: Different lasers and techniques for proliferative diabetic retinopathy
Comparison: 8 Extended targeted PRP versus standard PRP
Outcome: 4 Change in central macular thickness
Study or subgroup Extended Standard
Mean
Difference
Mean
Difference
N Mean(SD)[ m] N Mean(SD)[ m] IV,Fixed,95% CI IV,Fixed,95% CI
Nikkhah 2017 (1) 135 285 (40) 135 281 (44) 4.00 [ -6.03, 14.03 ]
-20 -10 0 10 20
Favours extended Favours standard
(1) central macular thickness at 3 months
A D D I T I O N A L T A B L E S
Table 1. Risk of bias
Item Low Unclear High
Sequence generation Computer generated list, ran-
dom table, other method of
generating random list
Not reported how list was gen-
erated. Trial may be described
as ’randomised’ but with no fur-
ther details
Alternate allocation, date of
birth, records (review authors
should exclude these RCTs)
Allocation concealment Central centre (web/telephone
access), sealed opaque
envelopes
Not reported how allocation
administered. Trial may be de-
scribed as ’randomised’ butwith
no further details
Investigator involved in treat-
ment allocation or treatment al-
location clearly not masked
Blinding (masking) of partici-
pants and personnel
Clearly stated that participants
and personnel (apart from doc-
tor) not aware of which lens re-
ceived
Described as ’double-masked’
with no information on who
was masked
No information onmasking. As
lenses different we will assume
that in absence of reporting on
this, participants and personnel
were not masked
Blinding (masking) of outcome
assessors
Clearly stated that outcome as-
sessors were masked
Described as ’double-masked’
with no information on who
was masked
No information onmasking. As
lenses different we will assume
that in absence of reporting on
this, outcome assessors were not
masked
Incomplete outcome data* Missing data less than 20% (i.e.
more than 80% follow-up) and
equal follow-up in both groups
Follow-up not reported ormiss-
ing data > 20% (i.e. follow-up
< 80%) but follow-up equal in
Follow-up different in each
group and related to outcome
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Table 1. Risk of bias (Continued)
and no obvious reason why loss
to follow-up should be related
to outcome
both groups
Selective outcome reporting All outcomes in protocol, tri-
als registry entry or both are re-
ported
No access to protocol or trials
registry entry
Outcomes in protocol or tri-
als registry entry selectively re-
ported
We have specified a cut-point of 20% loss to follow-up to enable consistent assessment of studies. We considered loss to follow-up of
greater than this to represent a potential risk of attrition bias.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Diabetic Retinopathy] explode all trees
#2 diabet* near/3 retinopath*
#3 proliferat* near/3 retinopath*
#4 diabet* near/3 maculopath*
#5 neovasculari?ation
#6 #1 or #2 or #3 or #4 or #5
#7 MeSH descriptor: [Light Coagulation] explode all trees
#8 MeSH descriptor: [Lasers, Gas] this term only
#9 photocoagulat*
#10 photo next coagulat*
#11 (focal or grid or scatter) near/3 laser*
#12 coagulat* or argon or krypton or YAG or diode or micropulse or Pascal or panretinal
#13 #7 or #9 or #10 or #11 or #12
#14 #6 and #13
Appendix 2. MEDLINE Ovid search strategy
1. Randomised controlled trial.pt.
2. (Randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp diabetic retinopathy/
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14. (diabet$ adj3 retinopath$).tw.
15. (proliferat$ adj3 retinopath$).tw.
16. (diabet$ adj3 maculopath$).tw.
17. neovasculari?ation.tw.
18. or/13-17
19. exp light coagulation/
20. lasers, gas/
21. photocoagulat$.tw.
22. (photo adj1 coagulat$).tw.
23. ((focal or grid or scatter) adj3 laser$).tw.
24. (coagulat$ or argon or krypton or YAG or diode or micropulse or Pascal or panretinal).tw.
25. or/19-24
26. 18 and 25
27. 12 and 26
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
Appendix 3. Embase Ovid search strategy
1. exp Randomised controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp diabetic retinopathy/
34. (diabet$ adj3 retinopath$).tw.
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35. (proliferat$ adj3 retinopath$).tw.
36. (diabet$ adj3 maculopath$).tw.
37. neovasculari?ation.tw.
38. or/33-37
39. exp laser coagulation/
40. argon laser/
41. photocoagulat$.tw.
42. (photo adj1 coagulat$).tw.
43. ((focal or grid or scatter) adj3 laser$).tw.
44. (coagulat$ or argon or krypton or YAG or diode or micropulse or Pascal or panretinal).tw.
45. or/39-44
46. 38 and 45
47. 32 and 46
Appendix 4. ISRCTN search strategy
diabetic retinopathy AND (laser OR photocoagulation OR coagulation OR argon OR krypton OR YAG OR diode OR micropulse
OR Pascal OR panretinal)
Appendix 5. ClinicalTrials.gov search strategy
diabetic retinopathy AND (laser OR photocoagulation OR coagulation OR argon OR krypton OR YAG OR diode OR micropulse
OR Pascal OR panretinal)
Appendix 6. WHO ICTRP search strategy
diabetic retinopathy = Condition AND laser OR photocoagulation OR coagulation OR argon OR krypton OR YAG OR diode OR
micropulse OR Pascal OR panretinal = Intervention
Appendix 7. Data on study characteristics
Mandatory items Optional items
Methods
Study design Parallel groupRCT (i.e. people randomised
to treatment)
Within-person RCT (i.e. eyes randomised
to treatment)
Cluster RCT (i.e. communities randomised
to treatment)
Cross-over RCT
Other, specify
Exclusions after randomisation
Losses to follow-up
Number randomised/analysed
Howweremissing data handled? (e.g. avail-
able case analysis, imputation methods)
Reported power calculation (Y/N), if yes,
sample size and power
Unusual study design/issues
Eyes or
Unit of randomisation/unit of analysis
One eye included in study, specify how eye
selected
Two eyes included in study, both eyes
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(Continued)
received same treatment, briefly specify
how analysed (best/worst/average/both and
adjusted for within person correlation/both
and not adjusted for within person correla-
tion) and specify if mixture one eye and two
eye
Two eyes included in study, eyes received
different treatments, specify if correct pair-
matched analysis done
Participants
Country Setting
Ethnic group
Equivalence of baseline characteristics (Y/
N)
Total number of participants This information should be collected for total
study population recruited into the study. If
these data are only reported for the people who
were followed up only, please indicate.
Number (%) of men and women
Average age and age range
Inclusion criteria
Exclusion criteria
Interventions
Intervention (n = )
Comparator (n = )
See MECIR 65 and 70
Number of people randomised to this
group
Drug (or intervention) name
Dose
Frequency
Route of administration
Outcomes
Primary and secondary outcomes as defined
in study reports
See MECIR R70
List outcomes
Adverse events reported (Y/N)
Length of follow-up and intervals at which
outcomes assessed
Planned/actual length of follow-up
Notes
Date conducted Specify dates of recruitment of participants
mm/yr to mm/yr
Full study name: (if applicable)
Reported subgroup analyses (Y/N)
Were trial investigators contacted?
Sources of funding
Declaration of interest
See MECIR 69
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We modified the inclusion criteria. We added krypton laser as an intervention to be excluded as it is not in common use.
We modified the outcomes as described Types of outcome measures.
We did not do the planned subgroup and sensitivity analyses because there were never more than 3 trials contributing to the analysis.
The planned analyses were as follows:
• Subgroup analyses: Quote from protocol “We will consider clinical sources of heterogeneity including the type of diabetes,
stability of glycaemic, lipid and blood pressure control, baseline visual acuity, baseline central macular thickness, and previous
treatments for PDR. We will conduct subgroup analyses to investigate clinical heterogeneity. When parameters are available, we will
stratify data according to baseline visual acuity worse than 6/24 Snellen equivalent (55 LogMAR letters), baseline CMT as measured
by OCT greater than 400 µm, and type 1 or 2 diabetes. We will only perform these subgroup analyses for the primary outcome of
this review.”
• Sensitivity analyses: Quote from protocol “ We will conduct sensitivity analyses to determine the impact of exclusion of studies
with lower methodological quality (defined as being at high risk of bias in one or more domains), unpublished data and industry-
funded studies. We will only perform the sensitivity analyses for the primary review outcomes.”
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We made the following amendments to the outcomes included in the summary of findings table.
• We added in the outcome “gain of 15 or more EDTRS letters” on the advice of a peer reviewer because it is a primary outcome
of our review and therefore was not appropriate to omit from the summary of findings table.
• We added in the new outcome of regression of PDR (see Types of outcome measures)
• We removed “visual field loss” because by adding these 2 new outcomes we had too many outcomes (8). We chose visual field
loss because there was very limited data reported on this.
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